WO2014010656A1 - Superior blood alcohol concentration reduction accelerating agent - Google Patents

Superior blood alcohol concentration reduction accelerating agent Download PDF

Info

Publication number
WO2014010656A1
WO2014010656A1 PCT/JP2013/068930 JP2013068930W WO2014010656A1 WO 2014010656 A1 WO2014010656 A1 WO 2014010656A1 JP 2013068930 W JP2013068930 W JP 2013068930W WO 2014010656 A1 WO2014010656 A1 WO 2014010656A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
powder
mass
turmeric
weight
Prior art date
Application number
PCT/JP2013/068930
Other languages
French (fr)
Japanese (ja)
Inventor
朋彦 中田
Original Assignee
興和株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 興和株式会社 filed Critical 興和株式会社
Priority to JP2014524858A priority Critical patent/JPWO2014010656A1/en
Publication of WO2014010656A1 publication Critical patent/WO2014010656A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a drug that quickly improves unpleasant symptoms such as leaning, nausea and hangover after alcohol consumption.
  • piperine or herbal medicine containing piperine is known as a herbal medicine having analgesic / gastric action, blood flow increasing action, antibacterial action, etc. It is effective for use as a patent document 3), a functional gastroenteropathy therapeutic agent (patent document 4), a use as a coldness improving agent (patent document 5), and a use as a swelling improving agent (patent document 6). It has been reported. It is also disclosed that piperine is contained in a liver dysfunction inhibitor (Patent Documents 7 and 8). However, it is not known how piperine or piperine-containing crude drugs affect alcohol metabolism.
  • JP-A-8-99890 JP 2003-226650 A JP 2000-154146 A JP 2006-327999 A JP 2003-040788 A JP 2006-104109 A Japanese Patent Laid-Open No. 5-262646 JP-A-2005-112846
  • An object of the present invention is to provide a drug that quickly improves unpleasant symptoms such as leaning, nausea and hangover after alcohol consumption.
  • the present inventor has conducted intensive research, and as a result, unexpectedly using piperine or piperine-containing crude drugs promotes a reduction in blood alcohol concentration, and piperine or piperine-containing crude drugs and turmeric. It was found that when used in combination, the reduction of blood alcohol concentration was further promoted, and the present invention was completed. That is, the present invention provides a blood alcohol concentration lowering accelerator (hereinafter referred to as the blood alcohol concentration lowering accelerator of the present invention) containing piperine or a piperine-containing crude drug. The present invention also provides a blood alcohol concentration lowering accelerator containing piperine or a piperine-containing crude drug and turmeric.
  • a blood alcohol concentration lowering accelerator hereinafter referred to as the blood alcohol concentration lowering accelerator of the present invention
  • the present invention it is possible to significantly reduce the blood alcohol concentration after alcohol intake, so that after the alcohol intake, nausea, hangover and other unpleasant symptoms, more specifically, after alcohol intake, Nausea (hangover, nausea, nausea, upset stomach, nausea, nausea), vomiting, hangover, stomach / abdominal bloating, stomach hyperacidity, stomach discomfort, indigestion, heartburn, chest pain, anorexia, It is effective for improving stomach weight, stomach weakness, and stomach pain.
  • the blood alcohol concentration lowering promoter of the present invention contains at least piperine or a piperine-containing crude drug.
  • piperine is represented by the compound name (2E, 4E) -1-piperidino-5- (1,3-benzodioxol-5-yl) -2,4-pentadien-1-one, It is a compound represented by the following formula.
  • Piperine is a pungent ingredient that is widely distributed in pepper and other cognate families, such as pepper, an analgesic / healthy stomach action, blood flow increasing action, antibacterial action, antiseptic action, insecticidal action, liver function protection / improvement action, etc. It is known to have
  • piperine that is separated and purified from chemically synthesized piperine or piperine-containing crude drugs can be used, but piperine-containing crude drugs may also be used.
  • the piperine-containing herbal medicine include pepper (Pipe nigrum L.), baboon (Pipe longum L. (aka: Indiana pepper), or Piper retrofractum Vahl (aka: Javanaga pepper, Giant beetle).
  • a mature or immature fruit, pericarp, seed, fruit spike, leaf, petiole, branch, root, flower or the like is used.
  • pepper when using pepper as a piperine-containing herbal medicine, black pepper obtained by drying immature fruit of pepper, white pepper obtained by removing the peel of mature fruit and drying, or immature fruit used for black pepper Further, it is preferable to use immature green fruits, and it is more preferable to use black pepper or immature green fruits.
  • immature green fruits when using pepper as a piperine-containing herbal medicine, black pepper obtained by drying immature fruit of pepper, white pepper obtained by removing the peel of mature fruit and drying, or immature fruit used for black pepper Further, it is preferable to use immature green fruits, and it is more preferable to use black pepper or immature green fruits.
  • These can be appropriately used as a dry powder, or an extract extracted with water, lower alcohol or a mixed solvent thereof.
  • These can be used as an extract obtained by drying a powder of dried Japanese butterfly or immature fruit, or an extract extracted with water, a lower alcohol or a mixed solvent thereof.
  • Specific examples include hihatsu, hihatsu powder, hihatsu extract, hihatsu-style extract, hihatsu dried extract, hihatsu soft extract, and the like.
  • Examples of commercially available products include Hihatsu powder (manufactured by Mikuni Co., Ltd.), Hihatsu extract MF (manufactured by Maruzen Pharmaceutical Co., Ltd.), and the like.
  • the content of piperine in the blood alcohol concentration lowering promoter of the present invention is preferably 0.0001 to 5% by weight, more preferably 0.001 to 1% by weight, based on the preparation.
  • the amount of piperine used per day for adults can be generally used in the range of 0.6 g / day, preferably 0.3 g / day, but the single dose is usually in the range of 0.0001 to 0.2 g. It is preferable to make it in the range of 0.0003 to 0.1 g.
  • the content of pepper in the blood alcohol concentration lowering promoter of the present invention is preferably 0.01 to 10% by weight, and 0.1 to 5% by weight in terms of the active ingredient based on the preparation. Further preferred.
  • the amount of pepper used per day for adults can be used in a range of up to 5 g / day, preferably 3 g / day, in terms of the active ingredient, but a single dose is usually 0.01 to A range of 2 g is preferable, and a range of 0.05 to 1 g is more preferable.
  • the content of baboon in the blood alcohol concentration lowering accelerator of the present invention is preferably 0.001 to 10% by weight, and 0.01 to 5% by weight in terms of the active ingredient based on the preparation. Further preferred. If the blending amount is less than 0.01% by weight, the effect may not be sufficiently obtained. If the blending amount exceeds 5% by weight, irritation such as pungent taste becomes strong, which may be unpreferable from the viewpoint of taking feeling.
  • the daily use amount of Hihatsu per adult can be used within the range of 5 g / day, preferably 3 g / day, in terms of the active ingredient, but the single dose is usually 0.001 to The range is preferably 2 g, more preferably 0.01 to 1 g.
  • the blood alcohol concentration lowering promoter of the present invention can further contain turmeric.
  • turmeric refers to ginger family turmeric (Curcuma longa (also known as autumn turmeric) or Curcuma aromatica (also known as spring turmeric)).
  • autumn turmeric and spring turmeric can be used, but it is preferable to use autumn turmeric.
  • Turmeric used in the present invention is preferably rhizome as it is or boiled except for pericarp, and further extracted with powdered turmeric powder, water, lower alcohol or a mixed solvent thereof. What was made into the extracted extract is still more preferable. Specific examples include turmeric, turmeric powder, turmeric extract, turmeric extract, turmeric dry extract, turmeric soft extract, and fermented turmeric, and turmeric powder or turmeric extract is preferred. Examples of commercially available products include turmeric powder (manufactured by Nippon Powder Chemical Co., Ltd.), turmeric extract (manufactured by Nippon Powder Chemical Co., Ltd., Maruzen Pharmaceutical Co., Ltd.), and the like.
  • the content of turmeric when blended with the blood alcohol concentration lowering promoter of the present invention is preferably 0.01 to 60% by weight, and 0.1 to 30% by weight based on the drug substance, relative to the preparation. % Is more preferable. If the blending amount is less than 0.01% by weight, the effect may not be sufficiently obtained. If the blending amount exceeds 60% by weight, the astringency becomes strong, which may be unfavorable in terms of taking feeling.
  • the amount of turmeric used per day for an adult can be used in the range of 10 g / day, preferably 6 g / day, in terms of the active ingredient, but the single dose is usually 0.01 to 1 in terms of the active ingredient.
  • a range of 6 g is preferable, and a range of 0.1 to 2 g is more preferable.
  • the weight ratio of piperine to turmeric is preferably 1: 0.05 to 1: 60000, It is more preferably 0.5 to 1: 6000, and particularly preferably 1: 5 to 1: 600.
  • the weight ratio between the piperine-containing crude drug and turmeric is preferably 1: 0.01 to 1: 120 in terms of the drug substance. 1: 0.1 to 1:60 is more preferable, and 1: 1 to 1:10 is particularly preferable.
  • the blood alcohol concentration lowering promoter of the present invention can be taken after alcohol intake (especially the next day), before alcohol intake, or even during alcohol intake. For example, it can be taken before or during alcohol consumption to prevent an increase in blood alcohol concentration, or it can be taken the day after alcohol is consumed at night and the blood alcohol concentration increased can be reduced. In addition, so-called hangover symptoms such as leaning and nausea caused by alcohol consumption can be improved and prevented.
  • the alcohol concentration lowering promoter of the present invention can be taken in 1 to 3 doses per day depending on the degree of discomfort or the expectation of its prevention.
  • the blood alcohol concentration lowering promoter of the present invention is preferably taken orally.
  • the blood alcohol concentration lowering promoter of the present invention has an action of promoting blood alcohol concentration lowering.
  • blood alcohol concentration lowering promoting effect means the action of reducing blood alcohol concentration, reducing blood alcohol concentration increased by drinking etc. compared to the case of no treatment, And suppression / prevention of an increase in blood alcohol concentration due to drinking or the like compared to no treatment. Therefore, the blood alcohol concentration lowering promoter of the present invention can be used for the improvement and / or prevention of various symptoms caused by alcohol consumption.
  • Nausea nausea, upset stomach, nausea, nausea), vomiting, hangover, stomach and abdominal bloating, stomach hyperacidity, stomach discomfort, indigestion, heartburn, chest pain, loss of appetite, stomach weight, stomach weakness It is effective in improving and / or preventing gastric pain.
  • alcohol is synonymous with ethanol.
  • the blood alcohol concentration reduction accelerator of the present invention may be used in combination with other blood alcohol concentration reduction accelerators. Moreover, the following active ingredient and additive can be mix
  • Examples of other blood alcohol level lowering accelerators include amino acids (alanine, glutamine), rainbow trout, cordyceps, citrus molasses (derived from Wenzhou oranges), ⁇ -lactalbumin, lactulose, maltitol, lactitol, glycerol, oleanolic acid, Presenegenin, Hederagenin, Protoesigenin, Caffeine, Chixetsunin, Kyokyo, Carnitine chloride, Glycylglycine, Pepino, Kuzune, Mung bean, Red bean, Santo, Malt, Kawamata, Kashiwa, Akiko, Sandhi, Light load, Fructose, Panax ginseng , Komi-sou hot water or Kazuwa-to fermented lactic acid bacteria, guava, dry activated yeast, fructose, ascorbic acid, aroma substance, citric acid, kinin and the like.
  • amino acids alanine,
  • antacids include synthetic hydrotalcite, magnesium oxide, magnesium silicate, magnesium aluminate silicate, aluminum silicate, magnesium aluminate metasilicate, magnesium hydroxide, aluminum hydroxide, magnesium alumina hydroxide, dihydroxy Aluminum aminoacetate, sodium hydrogencarbonate, calcium carbonate, magnesium carbonate, calcium hydrogenphosphate, aminoacetic acid, funnel extract and the like can be mentioned.
  • stomachic agents include aniseed fruit, aloe, fennel, turmeric, yak, life-prolonging grass, ogon, duckweed, auren, processed bonito, gadget, cuckoo, calamus root, dry cocoon, chaff, pheasant, keihi, gentian, kojin, koboku.
  • Liver function improving agents include, for example, liver hydrolyzate, Maria Thistle, Tabana carrot, indigo, dandelion, western dandelion, burdock, garlic, chrysanthemum, western yarrow, gardenia, sesame, asparagus, onion, chicory, medicinal salvia , Korean thistle (artichoke), wolfberry, legumes / iridaceae / rose family plants (for example, soybeans and kudzu, asparasas lineneas belonging to legumes), Japanese quail, elba de pasarinho, cetesangria, red buds, tea, Saiko, peach seed, peony skin, safflower, three crests, gadgets, turmeric, ⁇ -lipoic acid, flavonols, flavones, flavans, flavanols, catechins, isoflavones, lignanic acid, curcuminoids, glutelin, prolamin, G
  • Examples of the digestive agent include starch digestive enzyme, protein digestive enzyme, fat digestive enzyme, fibrin digestive enzyme, ursodesoxycholic acid, oxycoranoates, cholic acid, bile powder, bile extract (powder), dehydrocol Acid, animal gall (including yutan) and the like.
  • intestinal adjusting agent examples include live intestinal fungi components, natto kinase, akame koji, asenyaku, aloe, ubai, ketsumeishi, genokosho, plantago obata and the like.
  • Antidiarrheal agents include, for example, acrinol, berberine chloride, guaiacol, creosote, phenyl salicylate, guaiacol carbonate, berberine tannate, bismuth hyposalicylate, bismuth nitrate, bismuth carbonate, bismuth gallate, tannic acid, albumin tannate , Methylene thymol tannin, kaolin, pectin, medicinal charcoal, calcium lactate, Acacia yam, buckwheat, duckweed, auren, kudin, ganodermone, pentaploid, hawthorn, yellowtail, ivy.
  • analgesic and antispasmodic agents include oxyphencyclimine hydrochloride, dicyclomine hydrochloride, methixene hydrochloride, scopolamine hydrobromide, methyl atropine bromide, methyl anisotropine bromide, methyl scopolamine bromide, butyl scopolamine bromide, methyl bromide- l-hyostiamine, methylbenactidium bromide, belladonna extract, belladonna total alkaloid, iodopropamide, diphenylpiperidinomethyldioxolane iodide, funnel extract, funnel root total alkaloid citrate, papaverine hydrochloride, engosac, licorice, Examples include kokuboku and peonies.
  • gastric mucosa repairing agent examples include sodium azulenesulfonate, aldioxa, glycyrrhizic acid and salts thereof, and licorice extract, L-glutamine, copper chlorophyllin potassium, copper chlorophyllin sodium, histidine hydrochloride, porcine gastric wall pepsin degradation product, porcine gastric wall acid Hydrolysates, methylmethionine sulfonium chloride, red buds, engosac, licorice, sucralfate, rebamipide, marzulene, polaprezinc, sodium alginate, gefarnate, teprenone, troxipide, benexate betadex, prunotol, irsogladine maleate, sofalcone, etc. It is done.
  • vitamins include nicotinic acid amide, calcium pantothenate, biotin, vitamin B 1 or a derivative or salt thereof, vitamin B 2 or a derivative or salt thereof, vitamin B 6 or a derivative or salt thereof, vitamin C or Derivatives or salts thereof, vitamin E or derivatives or salts thereof, and the like.
  • antifoaming agent examples include dimethylpolysiloxane.
  • Antiemetics include, for example, granisetron, domperidone, sulpiride, ondansetron, azasetron, dimenhydrinate, metoclopramide, chlorpromazine, diphenidol hydrochloride, diphenhydramine, diphenhydramine hydrochloride, meclizine, promethazine, chlorpheniramine, chlorpheniramine maleate, Examples include amphetamine, atropine, bromvalerylurea, allylisopropylacetylurea, caffeine, theophylline, mint oil, l-menthol, dl-menthol, vitamin B6 and the like.
  • Additives include physiologically excipients, binders, disintegrants, lubricants, stabilizers, thickeners, solubilizers, preservatives, pH adjusters, colorants, sweeteners, etc. There are various acceptable types.
  • excipient examples include lactose, starches, crystalline cellulose, sucrose, mannitol, light anhydrous silicic acid and the like.
  • binder examples include hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol, pullulan and the like.
  • disintegrant examples include carmellose, carmellose calcium, croscarmellose sodium, crospovidone, corn starch, and low-substituted hydroxypropylcellulose.
  • Examples of the lubricant include magnesium stearate and talc.
  • the stabilizer examples include ascorbic acid, edetic acid, and salts thereof.
  • thickener examples include carmellose sodium, agar, gelatin, polyvinyl alcohol, polyvinyl pyrrolidone and the like.
  • solubilizer examples include hydrogenated oil, polyoxyethylene hydrogenated castor oil, nonionic surfactants such as sucrose fatty acid ester and glyceryl monostearate, and lecithin.
  • preservative examples include benzoic acid, sodium benzoate, methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, isopropyl paraoxybenzoate, butyl paraoxybenzoate, isobutyl paraoxybenzoate and the like.
  • pH adjuster examples include citric acid, malic acid, lactic acid, tartaric acid, acetic acid, hydrochloric acid, phosphoric acid, and salts thereof, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, and the like.
  • Examples of the colorant include titanium oxide, tar pigment, yellow No. 4, yellow No. 5, ferric oxide, yellow ferric oxide, red No. 3 and the like.
  • sweetening agent examples include sucrose, liquid sugar, fructose, fructose glucose liquid sugar, reduced maltose water candy, honey, caramel, sorbitol, maltitol, xylitol, erythritol, sucralose, stevia, glycyrrhizic acid or a salt thereof, aspartame, acesulfame Potassium etc. are mentioned.
  • the blood alcohol concentration lowering accelerator of the present invention can be taken alone, or it can be contained in a pharmaceutical composition together with other active ingredients and additives, or used in the form of a food additive or food supplement. It can also be included in various foods and drinks and provided as healthy foods and drinks. Moreover, according to the objective of this invention, it can manufacture in dosage forms, such as a liquid agent, a powder, a granule, a tablet, a chewable tablet, a film-coated tablet, a sugar-coated tablet, a soft capsule, a hard capsule, and a jelly agent by a well-known and usual technique.
  • a pharmaceutical or a food or drink containing the same is marked with an indication that it is used for the improvement and / or prevention of various symptoms caused by alcohol intake Good.
  • indications such as “to prevent or alleviate nausea, stomach upset and nausea”, “prevent hangover by drinking before drinking”, “energetic next day after drinking”, etc.
  • a display can be attached to the container and packaging means by a known method, whereby the blood alcohol concentration lowering accelerator of the present invention, the pharmaceutical or food and drink containing the same are variously attributed to alcohol intake. Since it is clearly shown that it is used for symptom improvement and / or prevention, the distinction from a normal agent or food and drink becomes clear.
  • Alcohol metabolism experiment An alcohol metabolism experiment was performed according to the following experimental method. Using Wistar male rats (8-9 weeks old) fasted overnight, a single sample of the drug (10 mL / kg) was orally administered, and 1.5 hours later, an aqueous ethanol solution (500 mg / kg) was added. Similarly, it was administered orally. Blood was collected from the tip of the tail at 30, 60, 90, and 120 minutes after administration of the aqueous ethanol solution, and the ethanol concentration in the blood was measured. The blood ethanol concentration collected at each time was measured using F kit alcohol (manufactured by JK International).
  • the drug sample is a control (saline), turmeric powder (autumn turmeric) 2000 mg / kg, chickweed powder (Java turmeric) 500 mg / kg, or turmeric powder (autumn turmeric) 2000 mg / kg + chick moth powder (Chinese pepper) ) 4 groups of 500 mg / kg each dissolved or suspended in physiological saline.
  • the numerical value of each group is a crude drug dose (mg) per body weight (kg) of a rat.
  • the ethanol concentration in blood when each drug sample was administered was plotted over time, and the results are shown in FIG. Next, the AUC of blood ethanol concentration 30 to 120 minutes after ethanol administration was calculated from the results of FIG. 1, and the results are shown in FIG.
  • the average AUC ratio of blood ethanol concentration in each group was 0.699 for the turmeric powder 2000 mg / kg group, 0.289 for the chickpea powder 500 mg / kg group, and 2000 mg / kg turmeric powder when the control was 1.
  • the combination group of Hihatsu powder 500 mg / kg is 0.102.
  • the product of the AUC ratios of the turmeric powder 2000 mg / kg group and the hihatsu powder 500 mg / kg group calculated according to the Burgi method (Keijiro Takagi et al .: Pharmacology, 1987, see Nanzan-do) is 0.202, and the above combination Greater than the group value. That is, a synergistic effect in the combination group was shown. From the above, compared with turmeric, which has been conventionally known to promote alcohol metabolism, hihatsu has a higher alcohol metabolic capacity improving effect, and further increases alcohol metabolic capacity by combining hihatsu and turmeric. It was shown that an effect can be obtained.
  • the following production examples 1 to 12 show production examples of the alcohol concentration lowering accelerator of the present invention.
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), carrot A kneaded product was prepared by adding 800 parts by mass of 70% ethanol to a mixed powder comprising 20 parts by mass of a dry extract, 70 parts by mass of polyvinyl alcohol, 30 parts by mass of carmellose calcium, 40 parts by mass of crystalline cellulose, and 1545 parts by mass of xylitol.
  • the kneaded product was extruded and granulated ( ⁇ 0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as B granules). Further, 6 parts by mass of l-menthol was adsorbed on 24 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granule, 3405 parts by mass of B granule, and 30 parts by mass of C fragrance powder were mixed by a mixer, and further packed by a packaging machine to obtain a granule having a single dose of 1.2 g.
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), carrot A kneaded product was prepared by adding 800 parts by mass of 70% ethanol to a mixed powder comprising 20 parts by mass of a dry extract, 70 parts by mass of polyvinyl alcohol, 30 parts by mass of carmellose calcium, 40 parts by mass of crystalline cellulose, and 1545 parts by mass of xylitol.
  • the kneaded product was extruded and granulated ( ⁇ 0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as B granules). Further, 6 parts by mass of l-menthol was adsorbed on 24 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granule, 3405 parts by mass of B granule, and 30 parts by mass of C fragrance powder were mixed by a mixer, and further packed by a packaging machine to obtain a granule having a single dose of 1.2 g.
  • ⁇ Production Example 9> Add 12 parts by mass of ethanol to the mixed powder consisting of 40 parts by mass of black pepper, 25 parts by mass of vitamin B1, 50 parts by mass of hardened oil, 20 parts by mass of glyceryl monostearate, 15 parts by mass of corn starch and 15 parts by mass of carmellose calcium. A compound was made. The kneaded product was extruded and granulated ( ⁇ 0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as A granules).
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), carrot A kneaded product was prepared by adding 800 parts by mass of 70% ethanol to a mixed powder comprising 20 parts by mass of a dry extract, 70 parts by mass of polyvinyl alcohol, 30 parts by mass of carmellose calcium, 40 parts by mass of crystalline cellulose, and 1545 parts by mass of xylitol.
  • the kneaded product was extruded and granulated ( ⁇ 0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as B granules). Further, 6 parts by mass of l-menthol was adsorbed on 24 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granule, 3405 parts by mass of B granule, and 30 parts by mass of C fragrance powder were mixed by a mixer, and further packed by a packaging machine to obtain a granule having a single dose of 1.2 g.
  • a mass part was added and the kneaded material was manufactured.
  • the kneaded product was extruded and granulated ( ⁇ 0.5 mm), dried and sized to obtain granules (hereinafter referred to as A granules).
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), show Add 700 parts by mass of 90% ethanol to a mixed powder consisting of 100 parts by mass of carp powder, 20 parts by mass of dried carrot extract, 90 parts by mass of hydroxypropyl cellulose, 30 parts by mass of carmellose calcium, 30 parts by mass of crystalline cellulose, and 1445 parts by mass of erythritol. A kneaded product was made.
  • the kneaded product was dried and sized to obtain granules (hereinafter referred to as B granules). Further, 4 parts by mass of l-menthol was adsorbed on 16 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granules, 3415 parts by mass of B granules, and 20 parts by mass of C fragrance powder were mixed with a mixer and further packaged with a packaging machine to obtain a granule having a single dose of 1.2 g.
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), show Add 700 parts by mass of 90% ethanol to a mixed powder consisting of 100 parts by mass of carp powder, 20 parts by mass of dried carrot extract, 90 parts by mass of hydroxypropyl cellulose, 30 parts by mass of carmellose calcium, 30 parts by mass of crystalline cellulose, and 1445 parts by mass of erythritol. A kneaded product was made.
  • the kneaded product was dried and sized to obtain granules (hereinafter referred to as B granules). Further, 4 parts by mass of l-menthol was adsorbed on 16 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granules, 3415 parts by mass of B granules, and 20 parts by mass of C fragrance powder were mixed with a mixer and further packaged with a packaging machine to obtain a granule having a single dose of 1.2 g.
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), show Add 700 parts by mass of 90% ethanol to a mixed powder consisting of 100 parts by mass of carp powder, 20 parts by mass of dried carrot extract, 90 parts by mass of hydroxypropyl cellulose, 30 parts by mass of carmellose calcium, 30 parts by mass of crystalline cellulose, and 1445 parts by mass of erythritol. A kneaded product was made.
  • the kneaded product was dried and sized to obtain granules (hereinafter referred to as B granules). Further, 4 parts by mass of l-menthol was adsorbed on 16 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granules, 3415 parts by mass of B granules, and 20 parts by mass of C fragrance powder were mixed with a mixer and further packaged with a packaging machine to obtain a granule having a single dose of 1.2 g.
  • the drug of the present invention contains piperine or a piperine-containing crude drug and turmeric, unpleasant symptoms such as leaning, nausea and hangover after alcohol consumption can be quickly improved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided is a blood alcohol concentration reduction accelerating agent which rapidly improves various unpleasant symptoms caused after alcohol consumption such as bloating, nausea and hangover. The blood alcohol concentration reduction accelerating agent is obtained by adding piperine or a piperine-containing crude drug to a preparation.

Description

優れた血中アルコール濃度低下促進剤Excellent promoter for lowering blood alcohol concentration
　本発明は、アルコール摂取後のもたれ、吐き気、二日酔い等の不快な諸症状を速やかに改善する薬剤に関する。 The present invention relates to a drug that quickly improves unpleasant symptoms such as leaning, nausea and hangover after alcohol consumption.
　一般に、アルコールの過剰摂取は、もたれ、吐き気、二日酔い等の不快な諸症状を引き起こす事が知られている。そのため、これら二日酔い等の不快な諸症状を改善するために、生薬や制酸剤等を組み合わせた胃腸薬が多数市販されている。しかし、未だ十分な効果が得られないといった問題から、新たな薬剤の研究が種々行われている。そのような研究としては、例えば、加工大蒜、ニンジン及び制酸剤を配合したもの（特許文献１）、オウゴン、ウコン及びショウキョウを配合したもの（特許文献２）等が知られている。しかし、これらの研究では、十分な効果が得られているとは言い難い。また、十分な効果を得るためには服用量を多くする必要があり、それに伴うコンプライアンスの低下や他の薬効成分の配合の制限等の問題を生じ、必ずしも満足のいくものではない。 Generally, it is known that excessive intake of alcohol causes unpleasant symptoms such as leaning, nausea and hangover. For this reason, many gastrointestinal drugs combined with herbal medicines and antacids are commercially available to improve these unpleasant symptoms such as hangover. However, various researches on new drugs have been conducted due to the problem that sufficient effects are not yet obtained. As such researches, for example, a blend of processed potato, carrot and antacid (Patent Document 1), a blend of oxon, turmeric and shochu (Patent Document 2) are known. However, it cannot be said that sufficient effects have been obtained in these studies. In addition, in order to obtain a sufficient effect, it is necessary to increase the dose, which causes problems such as a decrease in compliance and restrictions on the combination of other medicinal ingredients, which are not always satisfactory.
　ところで、ピペリン又はピペリンを含有する生薬（コショウ、ヒハツ等）は、鎮痛・健胃作用、血流増加作用、抗菌作用などを有する生薬として知られており、ヘリコバクター・ピロリに対する抗菌剤としての使用（特許文献３）や機能性胃腸症治療剤としての使用（特許文献４）、冷え性改善剤としての使用（特許文献５）、むくみの改善剤としての使用（特許文献６）に有効であることが報告されている。また、ピペリンを肝機能障害抑制剤に含有させることも開示されている（特許文献７、８）。しかし、ピペリン又はピペリン含有生薬がアルコール代謝にどのような影響を与えるかについては知られていない。 By the way, piperine or herbal medicine containing piperine (pepper, hihatsu, etc.) is known as a herbal medicine having analgesic / gastric action, blood flow increasing action, antibacterial action, etc. It is effective for use as a patent document 3), a functional gastroenteropathy therapeutic agent (patent document 4), a use as a coldness improving agent (patent document 5), and a use as a swelling improving agent (patent document 6). It has been reported. It is also disclosed that piperine is contained in a liver dysfunction inhibitor (Patent Documents 7 and 8). However, it is not known how piperine or piperine-containing crude drugs affect alcohol metabolism.
特開平８－９９８９０号公報JP-A-8-99890 特開２００３－２２６６５０号公報JP 2003-226650 A 特開２０００－１５４１４６号公報JP 2000-154146 A 特開２００６－３２７９９９号公報JP 2006-327999 A 特開２００３－０４０７８８号公報JP 2003-040788 A 特開２００６－１０４１０９号公報JP 2006-104109 A 特開平５－２６２６４６号公報Japanese Patent Laid-Open No. 5-262646 特開２００５－１１２８４６公報JP-A-2005-112846
　本発明の目的は、アルコール摂取後のもたれ、吐き気、二日酔い等の不快な諸症状を速やかに改善する薬剤を提供することにある。 An object of the present invention is to provide a drug that quickly improves unpleasant symptoms such as leaning, nausea and hangover after alcohol consumption.
　斯かる実情に鑑み、本発明者は鋭意研究を行った結果、意外にもピペリン又はピペリン含有生薬を使用すると、血中アルコール濃度の低下を促進すること、及びピペリン又はピペリン含有生薬とウコンとを併用すると、血中アルコール濃度の低下をさらに促進することを見出し、本発明を完成した。
　すなわち、本発明は、ピペリン又はピペリン含有生薬を含有する血中アルコール濃度低下促進剤（以降、本発明の血中アルコール濃度低下促進剤という）を提供するものである。また、本発明は、ピペリン又はピペリン含有生薬と、ウコンとを含有する血中アルコール濃度低下促進剤を提供するものである。 In view of such circumstances, the present inventor has conducted intensive research, and as a result, unexpectedly using piperine or piperine-containing crude drugs promotes a reduction in blood alcohol concentration, and piperine or piperine-containing crude drugs and turmeric. It was found that when used in combination, the reduction of blood alcohol concentration was further promoted, and the present invention was completed.
That is, the present invention provides a blood alcohol concentration lowering accelerator (hereinafter referred to as the blood alcohol concentration lowering accelerator of the present invention) containing piperine or a piperine-containing crude drug. The present invention also provides a blood alcohol concentration lowering accelerator containing piperine or a piperine-containing crude drug and turmeric.
　本発明によれば、アルコール摂取後の血中アルコール濃度を有意に低下させることができるため、アルコール摂取後のもたれ、吐き気、二日酔い等の不快な諸症状、より詳細にはアルコール摂取後のもたれ、吐き気（二日酔い・悪酔のむかつき、むかつき、胃のむかつき、嘔気、悪心）、嘔吐、二日酔い、胃部・腹部膨満感、胃酸過多、胃部不快感、消化不良、胸やけ、胸つかえ、食欲不振、胃重、胃弱、胃痛等の改善に有効である。 According to the present invention, it is possible to significantly reduce the blood alcohol concentration after alcohol intake, so that after the alcohol intake, nausea, hangover and other unpleasant symptoms, more specifically, after alcohol intake, Nausea (hangover, nausea, nausea, upset stomach, nausea, nausea), vomiting, hangover, stomach / abdominal bloating, stomach hyperacidity, stomach discomfort, indigestion, heartburn, chest pain, anorexia, It is effective for improving stomach weight, stomach weakness, and stomach pain.
エタノール投与後における各薬剤試料を投与した際の血中エタノール濃度の経時変化を表すグラフである。It is a graph showing the time-dependent change of the blood ethanol concentration at the time of administering each chemical | medical agent sample after ethanol administration. エタノール投与後３０分から１２０分の血中エタノール濃度のＡＵＣを表すグラフである。It is a graph showing AUC of blood ethanol concentration 30 minutes to 120 minutes after ethanol administration.
　以下、本発明について詳細に説明する。 Hereinafter, the present invention will be described in detail.
　本発明の血中アルコール濃度低下促進剤は、少なくともピペリン又はピペリン含有生薬を含有する。
　本発明においてピペリンとは、化合物名（２Ｅ，４Ｅ）－１－ピペリジノ－５－（１，３－ベンゾジオキソール－５－イル）－２，４－ペンタジエン－１－オンで表わされ、下記式で示される化合物である。 The blood alcohol concentration lowering promoter of the present invention contains at least piperine or a piperine-containing crude drug.
In the present invention, piperine is represented by the compound name (2E, 4E) -1-piperidino-5- (1,3-benzodioxol-5-yl) -2,4-pentadien-1-one, It is a compound represented by the following formula.
Figure JPOXMLDOC01-appb-C000001
Figure JPOXMLDOC01-appb-C000001
　ピペリンは、コショウ科コショウの他、ヒハツ等の同族各種に広く分布する辛味成分であり、鎮痛・健胃作用、血流増加作用、抗菌作用、防腐作用、殺虫作用、肝機能保護・改善作用などを有することが知られている。 Piperine is a pungent ingredient that is widely distributed in pepper and other cognate families, such as pepper, an analgesic / healthy stomach action, blood flow increasing action, antibacterial action, antiseptic action, insecticidal action, liver function protection / improvement action, etc. It is known to have
　本発明の血中アルコール濃度低下促進剤においては、化学合成されたピペリン又はピペリン含有生薬から分離・精製されたピペリンを使用することも可能であるが、ピペリン含有生薬を使用してもよい。
　ピペリン含有生薬としては、コショウ（Ｐｉｐｅｒ　ｎｉｇｒｕｍ　Ｌ．）、又はヒハツ（Ｐｉｐｅｒ　ｌｏｎｇｕｍ　Ｌ．（別名：インドナガコショウ）又はＰｉｐｅｒ　ｒｅｔｒｏｆｒａｃｔｕｍ　Ｖａｈｌ（別名：ジャワナガコショウ、ヒハツモドキ））が挙げられる。
　本発明におけるピペリン含有生薬は、成熟したまたは未成熟の、果実、果皮、種子、果穂、葉、葉柄、枝、根、花等を原料としたものが用いられる。 In the blood alcohol concentration lowering accelerator of the present invention, piperine that is separated and purified from chemically synthesized piperine or piperine-containing crude drugs can be used, but piperine-containing crude drugs may also be used.
Examples of the piperine-containing herbal medicine include pepper (Pipe nigrum L.), baboon (Pipe longum L. (aka: Indiana pepper), or Piper retrofractum Vahl (aka: Javanaga pepper, Giant beetle).
As the piperine-containing crude drug in the present invention, a mature or immature fruit, pericarp, seed, fruit spike, leaf, petiole, branch, root, flower or the like is used.
　本発明においてピペリン含有生薬としてコショウを使用する場合は、コショウの未成熟果実を乾燥させた黒胡椒、成熟果実の外果皮を除去して乾燥させた白胡椒、又は黒胡椒に用いる未成熟果実より更に未成熟な緑色の果実を使用することが好ましく、黒胡椒又は未成熟な緑色の果実を使用することがさらに好ましい。これらは、適宜、乾燥粉末や、水、低級アルコール又はそれらの混合溶媒で抽出した抽出エキスとして使用できる。 In the present invention, when using pepper as a piperine-containing herbal medicine, black pepper obtained by drying immature fruit of pepper, white pepper obtained by removing the peel of mature fruit and drying, or immature fruit used for black pepper Further, it is preferable to use immature green fruits, and it is more preferable to use black pepper or immature green fruits. These can be appropriately used as a dry powder, or an extract extracted with water, lower alcohol or a mixed solvent thereof.
　また、本発明におけるピペリン含有生薬としてヒハツを使用する場合は、インドナガコショウ（Ｐｉｐｅｒ　ｌｏｎｇｕｍ　Ｌ．）又はジャワナガコショウ（Ｐｉｐｅｒ　ｒｅｔｒｏｆｒａｃｔｕｍ　Ｖａｈｌ）のいずれでもよい。なお、ヒハツはナガコショウ（ロングペッパー）とも呼ばれ、植物分類学的に、狭義にはインドナガコショウをヒハツとし、それと区別するためにジャワナガコショウをヒハツモドキとする文献もあるが、いずれもその果穂にはピペリンを含有し、同様の薬理作用を有することから本発明では両方をヒハツとして扱う。
　本発明におけるヒハツを使用する場合は、その果穂又は未成熟果穂を使用したものであることが好ましい。これらは、適宜、ヒハツの果穂又は未成熟果穂を乾燥させて粉末にしたヒハツ末や、水、低級アルコール又はそれらの混合溶媒で抽出した抽出エキスとして使用できる。具体的には、ヒハツ、ヒハツ末、ヒハツエキス、ヒハツ流エキス、ヒハツ乾燥エキス、ヒハツ軟稠エキス等が挙げられ、ヒハツ末であることが好ましい。市販品としては、例えば、ヒハツ末（三國株式会社製）、ヒハツエキスＭＦ（丸善製薬株式会社製）等が挙げられる。 In the present invention, when using Japanese cherries as the piperine-containing crude drug, either Indian long pepper (Pipe longum L.) or Java red pepper (Pipe retrofractum Vahl) may be used. In addition, Hibatsu is also called Naga Pepper (long pepper), and there is a literature in which, in a narrow sense, Indian Naga Pepper is Hibatsu in a narrow sense, and Java Naga Pepper is Hibachimodo to distinguish it. Since the spikelet contains piperine and has the same pharmacological action, both are treated as baboons in the present invention.
When using the baboon in the present invention, it is preferable to use the fruit head or immature fruit head. These can be used as an extract obtained by drying a powder of dried Japanese butterfly or immature fruit, or an extract extracted with water, a lower alcohol or a mixed solvent thereof. Specific examples include hihatsu, hihatsu powder, hihatsu extract, hihatsu-style extract, hihatsu dried extract, hihatsu soft extract, and the like. Examples of commercially available products include Hihatsu powder (manufactured by Mikuni Co., Ltd.), Hihatsu extract MF (manufactured by Maruzen Pharmaceutical Co., Ltd.), and the like.
　本発明の血中アルコール濃度低下促進剤におけるピペリンの含有量は、製剤に対して０．０００１～５重量％であるのが好ましく、０．００１～１重量％であるのがさらに好ましい。
　なお、成人１日当りのピペリンの使用量は通常０．６ｇ／日、好ましくは０．３ｇ／日までの範囲で使用できるが、１回服用量は、通常０．０００１～０．２ｇの範囲にすることが好ましく、０．０００３～０．１ｇの範囲にすることがさらに好ましい。 The content of piperine in the blood alcohol concentration lowering promoter of the present invention is preferably 0.0001 to 5% by weight, more preferably 0.001 to 1% by weight, based on the preparation.
In addition, the amount of piperine used per day for adults can be generally used in the range of 0.6 g / day, preferably 0.3 g / day, but the single dose is usually in the range of 0.0001 to 0.2 g. It is preferable to make it in the range of 0.0003 to 0.1 g.
　本発明の血中アルコール濃度低下促進剤におけるコショウの含有量は、製剤に対して原生薬換算量で０．０１～１０重量％であるのが好ましく、０．１～５重量％であるのがさらに好ましい。
　なお、成人１日当りのコショウの使用量は原生薬換算量で通常５ｇ／日、好ましくは３ｇ／日までの範囲で使用できるが、１回服用量は、原生薬換算量で通常０．０１～２ｇの範囲にすることが好ましく、０．０５～１ｇの範囲にすることがさらに好ましい。 The content of pepper in the blood alcohol concentration lowering promoter of the present invention is preferably 0.01 to 10% by weight, and 0.1 to 5% by weight in terms of the active ingredient based on the preparation. Further preferred.
In addition, the amount of pepper used per day for adults can be used in a range of up to 5 g / day, preferably 3 g / day, in terms of the active ingredient, but a single dose is usually 0.01 to A range of 2 g is preferable, and a range of 0.05 to 1 g is more preferable.
　本発明の血中アルコール濃度低下促進剤におけるヒハツの含有量は、製剤に対して原生薬換算量で０．００１～１０重量％であるのが好ましく、０．０１～５重量％であるのがさらに好ましい。この配合量が０．０１重量％未満では効果が十分に得られにくい場合があり、また５重量％を超えると辛味等の刺激が強くなり服用感の面で好ましくない場合がある。
　なお、成人１日当りのヒハツの使用量は原生薬換算量で通常５ｇ／日、好ましくは３ｇ／日までの範囲で使用できるが、１回服用量は、原生薬換算量で通常０．００１～２ｇの範囲にすることが好ましく、０．０１～１ｇの範囲にすることがさらに好ましい。 The content of baboon in the blood alcohol concentration lowering accelerator of the present invention is preferably 0.001 to 10% by weight, and 0.01 to 5% by weight in terms of the active ingredient based on the preparation. Further preferred. If the blending amount is less than 0.01% by weight, the effect may not be sufficiently obtained. If the blending amount exceeds 5% by weight, irritation such as pungent taste becomes strong, which may be unpreferable from the viewpoint of taking feeling.
In addition, the daily use amount of Hihatsu per adult can be used within the range of 5 g / day, preferably 3 g / day, in terms of the active ingredient, but the single dose is usually 0.001 to The range is preferably 2 g, more preferably 0.01 to 1 g.
　また、本発明の血中アルコール濃度低下促進剤は、さらにウコンを含有することができる。
　ここで、本発明においてウコンとは、ショウガ科ウコン（Ｃｕｒｃｕｍａ　ｌｏｎｇａ（別名：秋ウコン）、又はＣｕｒｃｕｍａ　ａｒｏｍａｔｉｃａ（別名：春ウコン））のことである。本発明では秋ウコン及び春ウコンのいずれも使用することができるが、秋ウコンを使用することが好ましい。
　本発明で使用するウコンは、根茎をそのまま、又は周皮を除き湯通ししたものであることが好ましく、さらにそれを乾燥させて粉末にしたウコン末や、水、低級アルコール又はそれらの混合溶媒で抽出した抽出エキスにしたものがさらに好ましい。具体的には、ウコン、ウコン末、ウコンエキス、ウコン流エキス、ウコン乾燥エキス、ウコン軟稠エキス、発酵ウコン等が挙げられ、ウコン末又はウコン流エキスであることが好ましい。市販品としては、例えば、ウコン末（日本粉末薬品株式会社製）、ウコン流エキス（日本粉末薬品株式会社製、丸善製薬株式会社製）等が挙げられる。 Moreover, the blood alcohol concentration lowering promoter of the present invention can further contain turmeric.
Here, in the present invention, turmeric refers to ginger family turmeric (Curcuma longa (also known as autumn turmeric) or Curcuma aromatica (also known as spring turmeric)). In the present invention, both autumn turmeric and spring turmeric can be used, but it is preferable to use autumn turmeric.
Turmeric used in the present invention is preferably rhizome as it is or boiled except for pericarp, and further extracted with powdered turmeric powder, water, lower alcohol or a mixed solvent thereof. What was made into the extracted extract is still more preferable. Specific examples include turmeric, turmeric powder, turmeric extract, turmeric extract, turmeric dry extract, turmeric soft extract, and fermented turmeric, and turmeric powder or turmeric extract is preferred. Examples of commercially available products include turmeric powder (manufactured by Nippon Powder Chemical Co., Ltd.), turmeric extract (manufactured by Nippon Powder Chemical Co., Ltd., Maruzen Pharmaceutical Co., Ltd.), and the like.
　本発明の血中アルコール濃度低下促進剤にウコンを配合する場合の含有量は、製剤に対して、原生薬換算量で０．０１～６０重量％であるのが好ましく、０．１～３０重量％であるのがさらに好ましい。この配合量が０．０１重量％未満では効果が十分に得られにくい場合があり、また６０重量％を超えると渋味が強くなり服用感の面で好ましくない場合がある。 The content of turmeric when blended with the blood alcohol concentration lowering promoter of the present invention is preferably 0.01 to 60% by weight, and 0.1 to 30% by weight based on the drug substance, relative to the preparation. % Is more preferable. If the blending amount is less than 0.01% by weight, the effect may not be sufficiently obtained. If the blending amount exceeds 60% by weight, the astringency becomes strong, which may be unfavorable in terms of taking feeling.
　なお、成人１日当りのウコンの使用量は原生薬換算量で通常１０ｇ／日、好ましくは６ｇ／日までの範囲で使用できるが、１回服用量は、原生薬換算量で通常０．０１～６ｇの範囲にすることが好ましく、０．１～２ｇの範囲にすることがさらに好ましい。 In addition, the amount of turmeric used per day for an adult can be used in the range of 10 g / day, preferably 6 g / day, in terms of the active ingredient, but the single dose is usually 0.01 to 1 in terms of the active ingredient. A range of 6 g is preferable, and a range of 0.1 to 2 g is more preferable.
　本発明の血中アルコール濃度低下促進剤にウコンを配合する場合において、ピペリンとウコン（原生薬換算量）の重量比としては、１：０．０５～１：６００００であるのが好ましく、１：０．５～１：６０００であるのがさらに好ましく、１：５～１：６００であるのが特に好ましい。 In the case where turmeric is blended in the blood alcohol concentration lowering promoter of the present invention, the weight ratio of piperine to turmeric (raw material equivalent amount) is preferably 1: 0.05 to 1: 60000, It is more preferably 0.5 to 1: 6000, and particularly preferably 1: 5 to 1: 600.
　また、本発明の血中アルコール濃度低下促進剤にウコンを配合する場合において、ピペリン含有生薬とウコンの重量比としては、原生薬換算量で１：０．０１～１：１２０であるのが好ましく、１：０．１～１：６０であるのがさらに好ましく、１：１～１：１０であるのが特に好ましい。 In addition, when turmeric is blended in the blood alcohol concentration lowering promoter of the present invention, the weight ratio between the piperine-containing crude drug and turmeric is preferably 1: 0.01 to 1: 120 in terms of the drug substance. 1: 0.1 to 1:60 is more preferable, and 1: 1 to 1:10 is particularly preferable.
　本発明の血中アルコール濃度低下促進剤は、アルコール摂取後（特に翌日）でも、アルコール摂取前でも、或はアルコール摂取中でも服用できる。例えば、アルコール摂取前または摂取中に服用して血中アルコール濃度の上昇を予防することができるし、夜にアルコールを摂取した翌日に服用して上昇した血中アルコール濃度を低下させることもできるため、アルコール摂取に起因するもたれや吐き気等のいわゆる二日酔い症状を改善・予防することができる。
　また、本発明のアルコール濃度低下促進剤は、不快感、或はその予防の期待程度に応じて１日当り１～３回に分けて服用することができる。 The blood alcohol concentration lowering promoter of the present invention can be taken after alcohol intake (especially the next day), before alcohol intake, or even during alcohol intake. For example, it can be taken before or during alcohol consumption to prevent an increase in blood alcohol concentration, or it can be taken the day after alcohol is consumed at night and the blood alcohol concentration increased can be reduced. In addition, so-called hangover symptoms such as leaning and nausea caused by alcohol consumption can be improved and prevented.
The alcohol concentration lowering promoter of the present invention can be taken in 1 to 3 doses per day depending on the degree of discomfort or the expectation of its prevention.
　本発明の血中アルコール濃度低下促進剤は、経口で摂取することが好ましい。 The blood alcohol concentration lowering promoter of the present invention is preferably taken orally.
　本発明の血中アルコール濃度低下促進剤は、血中アルコール濃度低下を促進する作用を有する。本発明において「血中アルコール濃度低下促進作用」とは、血中のアルコール濃度を低減させる作用を意味し、飲酒等により上昇した血中アルコール濃度を無処置の場合に比して減少させること、及び飲酒等により血中アルコール濃度が上昇するのを無処置の場合に比して抑制・防止することを含む。
　したがって、本発明の血中アルコール濃度低下促進剤は、アルコール摂取に起因する諸症状の改善及び／又は予防のために用いることができ、具体的にはアルコール摂取後のもたれ、はきけ（二日酔い・悪酔のむかつき、むかつき、胃のむかつき、嘔気、悪心）、嘔吐、二日酔い、胃部・腹部膨満感、胃酸過多、胃部不快感、消化不良、胸やけ、胸つかえ、食欲不振、胃重、胃弱、胃痛等の改善及び／又は予防に有効である。
　なお、本明細書においてアルコールはエタノールと同義とする。 The blood alcohol concentration lowering promoter of the present invention has an action of promoting blood alcohol concentration lowering. In the present invention, "blood alcohol concentration lowering promoting effect" means the action of reducing blood alcohol concentration, reducing blood alcohol concentration increased by drinking etc. compared to the case of no treatment, And suppression / prevention of an increase in blood alcohol concentration due to drinking or the like compared to no treatment.
Therefore, the blood alcohol concentration lowering promoter of the present invention can be used for the improvement and / or prevention of various symptoms caused by alcohol consumption. Nausea, nausea, upset stomach, nausea, nausea), vomiting, hangover, stomach and abdominal bloating, stomach hyperacidity, stomach discomfort, indigestion, heartburn, chest pain, loss of appetite, stomach weight, stomach weakness It is effective in improving and / or preventing gastric pain.
In this specification, alcohol is synonymous with ethanol.
　本発明の血中アルコール濃度低下促進剤は、他の血中アルコール濃度低下促進剤と併用してもよい。
　また、本発明の血中アルコール濃度低下促進剤には、必要に応じて、以下の活性成分や添加物を配合することができる。活性成分としては、他の血中アルコール濃度低下促進剤、制酸剤、健胃剤、肝機能改善剤、消化剤、整腸剤、止瀉剤、鎮痛鎮痙剤、胃粘膜修復剤、ビタミン類、消泡剤、鎮吐剤等が挙げられる。 The blood alcohol concentration reduction accelerator of the present invention may be used in combination with other blood alcohol concentration reduction accelerators.
Moreover, the following active ingredient and additive can be mix | blended with the blood alcohol concentration fall promoter of this invention as needed. Active ingredients include other blood alcohol level lowering accelerators, antacids, healthy stomachs, liver function improvers, digestives, intestines, antipruritics, analgesics and antispasmodics, gastric mucosal repair agents, vitamins, antifoams, antiemetics Agents and the like.
　他の血中アルコール濃度低下促進剤としては、例えば、アミノ酸（アラニン、グルタミン）、シジミ、冬虫夏草、柑橘糖蜜（温州みかん由来）、α-ラクトアルブミン、ラクチュロース、マルチトール、ラクチトール、グリセロール、オレアノール酸、プレセネゲニン、ヘデラゲニン、プロトエシゲニン、カフェイン、チクセツニンジン、キキョウ、塩化カルニチン、グリシルグリシン、ペピノ、葛根、緑豆、赤小豆、山査、麦芽、川穹、蒼朮、決明子、砂仁、薄荷、果糖、オタネニンジン、キグシを含む加味雙和湯又は雙和湯乳酸菌発酵物、グアバ、乾燥活性酵母、フルクトース、アスコルビン酸、香気物質、クエン酸、キニン等が挙げられる。 Examples of other blood alcohol level lowering accelerators include amino acids (alanine, glutamine), rainbow trout, cordyceps, citrus molasses (derived from Wenzhou oranges), α-lactalbumin, lactulose, maltitol, lactitol, glycerol, oleanolic acid, Presenegenin, Hederagenin, Protoesigenin, Caffeine, Chixetsunin, Kyokyo, Carnitine chloride, Glycylglycine, Pepino, Kuzune, Mung bean, Red bean, Santo, Malt, Kawamata, Kashiwa, Akiko, Sandhi, Light load, Fructose, Panax ginseng , Komi-sou hot water or Kazuwa-to fermented lactic acid bacteria, guava, dry activated yeast, fructose, ascorbic acid, aroma substance, citric acid, kinin and the like.
　制酸剤としては、例えば、合成ヒドロタルサイト、酸化マグネシウム、ケイ酸マグネシウム、ケイ酸アルミン酸マグネシウム、ケイ酸アルミニウム、メタケイ酸アルミン酸マグネシウム、水酸化マグネシウム、水酸化アルミニウム、水酸化アルミナマグネシウム、ジヒドロキシアルミニウムアミノアセテート、炭酸水素ナトリウム、炭酸カルシウム、炭酸マグネシウム、リン酸水素カルシウム、アミノ酢酸、ロートエキス等が挙げられる。 Examples of antacids include synthetic hydrotalcite, magnesium oxide, magnesium silicate, magnesium aluminate silicate, aluminum silicate, magnesium aluminate metasilicate, magnesium hydroxide, aluminum hydroxide, magnesium alumina hydroxide, dihydroxy Aluminum aminoacetate, sodium hydrogencarbonate, calcium carbonate, magnesium carbonate, calcium hydrogenphosphate, aminoacetic acid, funnel extract and the like can be mentioned.
　健胃剤としては、例えば、アニス実、アロエ、ウイキョウ、ウコン、ウヤク、延命草、オウゴン、オウバク、オウレン、加工大蒜、ガジュツ、カッコウ、カラムス根、乾薑、枳殻、キジツ、ケイヒ、ゲンチアナ、コウジン、コウボク、ゴシュユ、コロンボ、コンズランゴ、サンシシ、サンショウ、山奈、シソシ、シュクシャ、ショウキョウ、ショウズク、青皮、石菖根、センタウリウム草、センブリ、ソウジュツ、ソヨウ、大茴香、ダイオウ、タクシャ、チクセツニンジン、チョウジ、チョレイ、チンピ、トウガラシ、トウヒ、動物胆（ユウタンを含む）、ニガキ、ニクズク、ニンジン、ハッカ（セイヨウハッカを含む）、ビャクジュツ、ブクリョウ、ホップ、ホミカエキス、睡菜葉（スイサイヨウ）、モッコウ、ヤクチ、リュウタン、リョウキョウ、ウイキョウ油、ケイヒ油、ショウキョウ油、ショウズク油、チョウジ油、トウヒ油、ハッカ油、レモン油、ｌ－メントール、ｄｌ－メントール、塩酸ベタイン、グルタミン酸塩酸塩、塩化カルニチン、塩化ベタネコール、乾燥酵母等が挙げられる。 Examples of stomachic agents include aniseed fruit, aloe, fennel, turmeric, yak, life-prolonging grass, ogon, duckweed, auren, processed bonito, gadget, cuckoo, calamus root, dry cocoon, chaff, pheasant, keihi, gentian, kojin, koboku. , Goshuyu, Colombo, Conslango, Sanshishi, Salamander, Yamana, Shisoshi, Shukusha, Shokyo, Shouzuku, Aohide, Ishizone, Centaurium grass, Sembli, Sowjutsu, Soyo, Otsuka, Daiou, Takusha, Chikusetsuninjin, Clove, Chorei, Chinpi, Pepper, Spruce, Animal Gall (including Yutan), Nigaki, Nikuzuku, Carrot, Pepper (including Pepper), Peacock, Buddlefish, Hop, Homika Extract, Sleepy Leaves (Sweet Pepper), Mokko, Yakuchi, Ryutan , Oyster, fennel oil, cinnamon oil, ginger oil, ginger oil, clove oil, spruce oil, peppermint oil, lemon oil, l-menthol, dl-menthol, betaine hydrochloride, glutamate hydrochloride, carnitine chloride, betanechol chloride, dry yeast Etc.
　肝機能改善剤としては、例えば、肝臓加水分解物、マリアアザミ、田七ニンジン、藍、タンポポ、西洋タンポポ、ゴボウ、ニンニク、キク、西洋ノコギリソウ、クチナシ、ゴマ、アスパラガス、タマネギ、チコリ、薬用サルビア、朝鮮アザミ（アーティチョーク）、クコ、マメ科・アヤメ科・バラ科の植物（例えば大豆やクズ、マメ科に属するアスパラサス・リネアリス）、ミヤマウズラ、エルバ・デ・パサリーニョ、セテサングリア、赤芽柏、紅茶、柴胡、桃仁、牡丹皮、紅花、三稜、ガジュツ、ウコン、α－リポ酸、フラボノール類、フラボン類、フラバン類、フラバノール類、カテキン類、イソフラボン類、リグナン酸、クルクミノイド類、グルテリン、プロラミン、グルタチオン、レシチン、バリン、ロイシン、イソロイシン、プロリン、アルギニン、アルギン酸、ヒスチジン、トリプトファン、キチンオリゴ糖、キトサンオリゴ糖、エタノールアミン、ホスホエタノールアミン、ホスホグリセロエタノールアミン、アラキドン酸、リノール酸、γ－リノレン酸、エイコサペンタエン酸、ドコサヘキサエン酸等が挙げられる。 Liver function improving agents include, for example, liver hydrolyzate, Maria Thistle, Tabana carrot, indigo, dandelion, western dandelion, burdock, garlic, chrysanthemum, western yarrow, gardenia, sesame, asparagus, onion, chicory, medicinal salvia , Korean thistle (artichoke), wolfberry, legumes / iridaceae / rose family plants (for example, soybeans and kudzu, asparasas lineneas belonging to legumes), Japanese quail, elba de pasarinho, cetesangria, red buds, tea, Saiko, peach seed, peony skin, safflower, three crests, gadgets, turmeric, α-lipoic acid, flavonols, flavones, flavans, flavanols, catechins, isoflavones, lignanic acid, curcuminoids, glutelin, prolamin, Glutathione, lecithin, valine, leucine, isoleucine, Examples include phosphorus, arginine, alginic acid, histidine, tryptophan, chitin oligosaccharide, chitosan oligosaccharide, ethanolamine, phosphoethanolamine, phosphoglyceroethanolamine, arachidonic acid, linoleic acid, γ-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, etc. It is done.
　消化剤としては、例えば、でんぷん消化酵素、たん白消化酵素、脂肪消化酵素、繊維素消化酵素、ウルソデスオキシコール酸、オキシコーラン酸塩類、コール酸、胆汁末、胆汁エキス（末）、デヒドロコール酸、動物胆（ユウタンを含む）等が挙げられる。 Examples of the digestive agent include starch digestive enzyme, protein digestive enzyme, fat digestive enzyme, fibrin digestive enzyme, ursodesoxycholic acid, oxycoranoates, cholic acid, bile powder, bile extract (powder), dehydrocol Acid, animal gall (including yutan) and the like.
　整腸剤としては、例えば、整腸生菌成分、納豆キナーゼ、赤芽柏、アセンヤク、アロエ、ウバイ、ケツメイシ、ゲンノショウコ、プランタゴ・オバタ等が挙げられる。 Examples of the intestinal adjusting agent include live intestinal fungi components, natto kinase, akame koji, asenyaku, aloe, ubai, ketsumeishi, genokosho, plantago obata and the like.
　止瀉剤としては、例えば、アクリノール、塩化ベルベリン、グアヤコール、クレオソート、サリチル酸フェニル、炭酸グアヤコール、タンニン酸ベルベリン、次サリチル酸ビスマス、次硝酸ビスマス、次炭酸ビスマス、次没食子酸ビスマス、タンニン酸、タンニン酸アルブミン、メチレンチモールタンニン、カオリン、ペクチン、薬用炭、乳酸カルシウム、アセンヤク、ウバイ、オウバク、オウレン、クジン、ゲンノショウコ、五倍子、サンザシ、センブリ、ヨウバイヒ等が挙げられる。 Antidiarrheal agents include, for example, acrinol, berberine chloride, guaiacol, creosote, phenyl salicylate, guaiacol carbonate, berberine tannate, bismuth hyposalicylate, bismuth nitrate, bismuth carbonate, bismuth gallate, tannic acid, albumin tannate , Methylene thymol tannin, kaolin, pectin, medicinal charcoal, calcium lactate, Acacia yam, buckwheat, duckweed, auren, kudin, ganodermone, pentaploid, hawthorn, yellowtail, ivy.
　鎮痛鎮痙剤としては、例えば、塩酸オキシフェンサイクリミン、塩酸ジサイクロミン、塩酸メチキセン、臭化水素酸スコポラミン、臭化メチルアトロピン、臭化メチルアニソトロピン、臭化メチルスコポラミン、臭化ブチルスコポラミン、臭化メチル－ｌ－ヒヨスチアミン、臭化メチルベナクチジウム、ベラドンナエキス、ベラドンナ総アルカロイド、ヨウ化イソプロパミド、ヨウ化ジフェニルピペリジノメチルジオキソラン、ロートエキス、ロート根総アルカロイドクエン酸塩、塩酸パパベリン、エンゴサク、カンゾウ、コウボク、シャクヤク等が挙げられる。 Examples of analgesic and antispasmodic agents include oxyphencyclimine hydrochloride, dicyclomine hydrochloride, methixene hydrochloride, scopolamine hydrobromide, methyl atropine bromide, methyl anisotropine bromide, methyl scopolamine bromide, butyl scopolamine bromide, methyl bromide- l-hyostiamine, methylbenactidium bromide, belladonna extract, belladonna total alkaloid, iodopropamide, diphenylpiperidinomethyldioxolane iodide, funnel extract, funnel root total alkaloid citrate, papaverine hydrochloride, engosac, licorice, Examples include kokuboku and peonies.
　胃粘膜修復剤としては、例えば、アズレンスルホン酸ナトリウム、アルジオキサ、グリチルリチン酸及びその塩類並びに甘草抽出物、Ｌ－グルタミン、銅クロロフィリンカリウム、銅クロロフィリンナトリウム、塩酸ヒスチジン、ブタ胃壁ペプシン分解物、ブタ胃壁酸加水分解物、メチルメチオニンスルホニウムクロライド、赤芽柏、エンゴサク、カンゾウ、スクラルファート、レバミピド、マーズレン、ポラプレジンク、アルギン酸ナトリウム、ゲファルナート、テプレノン、トロキシピド、塩酸ベネキサートベータデクス、プラウノトール、マレイン酸イルソグラジン、ソファルコン等が挙げられる。 Examples of the gastric mucosa repairing agent include sodium azulenesulfonate, aldioxa, glycyrrhizic acid and salts thereof, and licorice extract, L-glutamine, copper chlorophyllin potassium, copper chlorophyllin sodium, histidine hydrochloride, porcine gastric wall pepsin degradation product, porcine gastric wall acid Hydrolysates, methylmethionine sulfonium chloride, red buds, engosac, licorice, sucralfate, rebamipide, marzulene, polaprezinc, sodium alginate, gefarnate, teprenone, troxipide, benexate betadex, prunotol, irsogladine maleate, sofalcone, etc. It is done.
　ビタミン類としては、例えば、ニコチン酸アミド、パントテン酸カルシウム、ビオチン、ビタミンＢ1又はその誘導体もしくはその塩類、ビタミンＢ2又はその誘導体もしくはその塩類、ビタミンＢ6又はその誘導体もしくはその塩類、ビタミンＣ又はその誘導体もしくはその塩類、ビタミンＥ又はその誘導体もしくはその塩類等が挙げられる。 Examples of vitamins include nicotinic acid amide, calcium pantothenate, biotin, vitamin B 1 or a derivative or salt thereof, vitamin B 2 or a derivative or salt thereof, vitamin B 6 or a derivative or salt thereof, vitamin C or Derivatives or salts thereof, vitamin E or derivatives or salts thereof, and the like.
　消泡剤としては、例えばジメチルポリシロキサン等が挙げられる。 Examples of the antifoaming agent include dimethylpolysiloxane.
　鎮吐剤としては、例えば、グラニセトロン、ドンペリドン、スルピリド、オンダンセトロン、アザセトロン、ジメンヒドリナート、メトクロプラミド、クロルプロマジン、塩酸ジフェニドール、ジフェンヒドラミン、塩酸ジフェンヒドラミン、メクリジン、プロメタジン、クロルフェニラミン、マレイン酸クロルフェニラミン、アンフェタミン、アトロピン、ブロムワレリル尿素、アリルイソプロピルアセチル尿素、カフェイン、テオフィリン、ハッカ油、ｌ－メントール、ｄｌ－メントール、ビタミンＢ６等が挙げられる。 Antiemetics include, for example, granisetron, domperidone, sulpiride, ondansetron, azasetron, dimenhydrinate, metoclopramide, chlorpromazine, diphenidol hydrochloride, diphenhydramine, diphenhydramine hydrochloride, meclizine, promethazine, chlorpheniramine, chlorpheniramine maleate, Examples include amphetamine, atropine, bromvalerylurea, allylisopropylacetylurea, caffeine, theophylline, mint oil, l-menthol, dl-menthol, vitamin B6 and the like.
　また、添加物としては、賦形剤、結合剤、崩壊剤、滑沢剤、安定化剤、増粘剤、可溶化剤、保存剤、ｐＨ調節剤、着色剤、甘味剤等、生理学的に許容される種々のものが挙げられる。 Additives include physiologically excipients, binders, disintegrants, lubricants, stabilizers, thickeners, solubilizers, preservatives, pH adjusters, colorants, sweeteners, etc. There are various acceptable types.
　賦形剤としては、例えば、乳糖、デンプン類、結晶セルロース、蔗糖、マンニトール、軽質無水ケイ酸等が挙げられる。 Examples of the excipient include lactose, starches, crystalline cellulose, sucrose, mannitol, light anhydrous silicic acid and the like.
　結合剤としては、例えば、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、ゼラチン、アルファー化デンプン、ポリビニルピロリドン、ポリビニルアルコール、プルラン等が挙げられる。 Examples of the binder include hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol, pullulan and the like.
　崩壊剤としては、例えば、カルメロース、カルメロースカルシウム、クロスカルメロースナトリウム、クロスポピドン、トウモロコシ澱粉、低置換度ヒドロキシプロピルセルロース等が挙げられる。 Examples of the disintegrant include carmellose, carmellose calcium, croscarmellose sodium, crospovidone, corn starch, and low-substituted hydroxypropylcellulose.
　滑沢剤としては、例えば、ステアリン酸マグネシウム、タルク等が挙げられる。 Examples of the lubricant include magnesium stearate and talc.
　安定化剤としては、例えば、アスコルビン酸、エデト酸、又はそれらの塩等が挙げられる。 Examples of the stabilizer include ascorbic acid, edetic acid, and salts thereof.
　増粘剤としては、例えば、カルメロースナトリウム、寒天、ゼラチン、ポリビニルアルコール、ポリビニルピロリドン等が挙げられる。 Examples of the thickener include carmellose sodium, agar, gelatin, polyvinyl alcohol, polyvinyl pyrrolidone and the like.
　可溶化剤としては、例えば、硬化油、ポリオキシエチレン硬化ヒマシ油、ショ糖脂肪酸エステルやモノステアリン酸グリセリン等の非イオン性界面活性剤、レシチン等が挙げられる。 Examples of the solubilizer include hydrogenated oil, polyoxyethylene hydrogenated castor oil, nonionic surfactants such as sucrose fatty acid ester and glyceryl monostearate, and lecithin.
　保存剤としては、例えば、安息香酸、安息香酸ナトリウム、パラオキシ安息香酸メチル、パラオキシ安息香酸エチル、パラオキシ安息香酸プロピル、パラオキシ安息香酸イソプロピル、パラオキシ安息香酸ブチル、パラオキシ安息香酸イソブチル等が挙げられる。 Examples of the preservative include benzoic acid, sodium benzoate, methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, isopropyl paraoxybenzoate, butyl paraoxybenzoate, isobutyl paraoxybenzoate and the like.
　ｐＨ調節剤としては、例えば、クエン酸、リンゴ酸、乳酸、酒石酸、酢酸、塩酸、リン酸、及びそれらの塩、水酸化ナトリウム、水酸化カリウム、水酸化マグネシウム、水酸化カルシウム等が挙げられる。 Examples of the pH adjuster include citric acid, malic acid, lactic acid, tartaric acid, acetic acid, hydrochloric acid, phosphoric acid, and salts thereof, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, and the like.
　着色剤としては、例えば、酸化チタン、タール色素、黄色４号、黄色５号、三二酸化鉄、黄色三二酸化鉄、赤色３号等が挙げられる。 Examples of the colorant include titanium oxide, tar pigment, yellow No. 4, yellow No. 5, ferric oxide, yellow ferric oxide, red No. 3 and the like.
　甘味剤としては、例えば、白糖、液糖、果糖、果糖ブドウ糖液糖、還元麦芽糖水アメ、ハチミツ、カラメル、ソルビトール、マルチトール、キシリトール、エリスリトール、スクラロース、ステビア、グリチルリチン酸またはその塩、アスパルテーム、アセスルファムカリウム等が挙げられる。 Examples of the sweetening agent include sucrose, liquid sugar, fructose, fructose glucose liquid sugar, reduced maltose water candy, honey, caramel, sorbitol, maltitol, xylitol, erythritol, sucralose, stevia, glycyrrhizic acid or a salt thereof, aspartame, acesulfame Potassium etc. are mentioned.
　本発明の血中アルコール濃度低下促進剤は、単独で服用することもできるし、又は他の活性成分や添加物と共に医薬品組成物に含有させることや、食品添加剤もしくは食品補助剤の態様で用いて種々の飲食品に含有させて健康飲食品として提供することもできる。
　また、本発明の目的に応じて公知慣用技術により液剤、散剤、顆粒剤、錠剤、チュアブル錠、フィルムコーティング錠、糖衣錠、軟カプセル剤、硬カプセル剤、ゼリー剤等の剤型に製造できる。 The blood alcohol concentration lowering accelerator of the present invention can be taken alone, or it can be contained in a pharmaceutical composition together with other active ingredients and additives, or used in the form of a food additive or food supplement. It can also be included in various foods and drinks and provided as healthy foods and drinks.
Moreover, according to the objective of this invention, it can manufacture in dosage forms, such as a liquid agent, a powder, a granule, a tablet, a chewable tablet, a film-coated tablet, a sugar-coated tablet, a soft capsule, a hard capsule, and a jelly agent by a well-known and usual technique.
　本発明の血中アルコール濃度低下促進剤、これを含有する医薬品又は飲食品は、アルコール摂取に起因する諸症状の改善及び／又は予防のために用いられるものである旨の表示を付してもよい。例えば「吐き気や胃もたれ・むかつきの予防や緩和に」「お酒を飲む前に飲んで、二日酔いを防止」「飲み会の次の日も元気に」等の表示が挙げられる。
　なお、このような表示は、公知の方法で容器包装手段に付すことができ、これによって本発明の血中アルコール濃度低下促進剤、これを含有する医薬品又は飲食品は、アルコール摂取に起因する諸症状の改善及び／又は予防のために用いられるものであることが明示されるので、通常の剤又は飲食物との区別が明確となる。 Even if the blood alcohol concentration lowering promoter of the present invention, a pharmaceutical or a food or drink containing the same is marked with an indication that it is used for the improvement and / or prevention of various symptoms caused by alcohol intake Good. For example, indications such as “to prevent or alleviate nausea, stomach upset and nausea”, “prevent hangover by drinking before drinking”, “energetic next day after drinking”, etc.
In addition, such a display can be attached to the container and packaging means by a known method, whereby the blood alcohol concentration lowering accelerator of the present invention, the pharmaceutical or food and drink containing the same are variously attributed to alcohol intake. Since it is clearly shown that it is used for symptom improvement and / or prevention, the distinction from a normal agent or food and drink becomes clear.
＜試験例１＞アルコール代謝実験
　下記実験方法に従ってアルコール代謝実験を行った。
　一晩絶食したウィスター(Wistar)系雄性ラット（８～９週齢）を用い、薬剤試料（１０ｍＬ／ｋｇ）を経口で単回投与し、その１．５時間後にエタノール水溶液(５００ｍg／ｋｇ)を同じく経口投与した。エタノール水溶液投与後３０、６０、９０、及び１２０分後に尾の先端から採血し、血中エタノール濃度を測定した。各時間に採取した血中エタノール濃度は、Ｆキット　アルコール（Ｊ．Ｋ．インターナショナル社製）を用いて測定した。薬剤試料は、コントロール（生理食塩水）、並びにウコン末（秋ウコン）２０００ｍｇ／ｋｇ、ヒハツ末（ジャワナガコショウ）５００ｍｇ／ｋｇ、または、ウコン末（秋ウコン）２０００ｍｇ／ｋｇ＋ヒハツ末（ジャワナガコショウ）５００ｍｇ／ｋｇをそれぞれ生理食塩水に溶解又は懸濁させたもの、の４群である。なお、各群の数値はラットの体重（ｋｇ）当たりの生薬投与量（ｍｇ）である。
　各薬剤試料を投与した際の血中エタノール濃度を経時的にプロットし、その結果を図１に示す。
　次に、図１の結果からエタノール投与後３０分から１２０分の血中エタノール濃度のＡＵＣを算出し、その結果を図２に示す。 <Test Example 1> Alcohol metabolism experiment An alcohol metabolism experiment was performed according to the following experimental method.
Using Wistar male rats (8-9 weeks old) fasted overnight, a single sample of the drug (10 mL / kg) was orally administered, and 1.5 hours later, an aqueous ethanol solution (500 mg / kg) was added. Similarly, it was administered orally. Blood was collected from the tip of the tail at 30, 60, 90, and 120 minutes after administration of the aqueous ethanol solution, and the ethanol concentration in the blood was measured. The blood ethanol concentration collected at each time was measured using F kit alcohol (manufactured by JK International). The drug sample is a control (saline), turmeric powder (autumn turmeric) 2000 mg / kg, chickweed powder (Java turmeric) 500 mg / kg, or turmeric powder (autumn turmeric) 2000 mg / kg + chick moth powder (Chinese pepper) ) 4 groups of 500 mg / kg each dissolved or suspended in physiological saline. In addition, the numerical value of each group is a crude drug dose (mg) per body weight (kg) of a rat.
The ethanol concentration in blood when each drug sample was administered was plotted over time, and the results are shown in FIG.
Next, the AUC of blood ethanol concentration 30 to 120 minutes after ethanol administration was calculated from the results of FIG. 1, and the results are shown in FIG.
　図１に示されるとおり、ウコン末２０００ｍｇ／ｋｇを投与した場合及びヒハツ末５００ｍｇ／ｋｇを投与した場合は、コントロールに対して血中エタノール濃度の上がり方が緩やかで、かつ血中アルコール濃度が有意に減少する結果が得られた。また、ヒハツ末５００ｍｇ／ｋｇを投与した場合は、ウコン末２０００ｍｇ／ｋｇを投与した場合に対しても、より血中エタノール濃度の上がり方が緩やかで、かつ血中アルコール濃度が有意に減少する結果となった。さらに、ウコン末２０００ｍｇ／ｋｇとヒハツ末５００ｍｇ／ｋｇとを併用投与した場合は、ヒハツ末５００ｍｇ／ｋｇのみを投与した場合に対して、より血中エタノール濃度の上がり方が緩やかで、かつ血中アルコール濃度が有意に減少する結果となった。
　図２に示されるとおり、各群平均の血中エタノール濃度のＡＵＣにおいても、ウコン末２０００ｍｇ／ｋｇを投与した場合及びヒハツ末５００ｍｇ／ｋｇを投与した場合は、コントロールに対して有意に血中エタノール濃度が有意に小さい結果となった。また、ヒハツ末５００ｍｇ／ｋｇを投与した場合は、ウコン末２０００ｍｇ／ｋｇを投与した場合に対しても、血中エタノール濃度が有意に小さい結果となった。さらにウコン末２０００ｍｇ／ｋｇとヒハツ末５００ｍｇ／ｋｇとを併用投与した場合は、ヒハツ末５００ｍｇ／ｋｇのみを投与した場合に対して、血中エタノール濃度が有意に小さい結果となった。ここで、各群平均の血中エタノール濃度のＡＵＣ比は、コントロールを１とした時、ウコン末２０００ｍｇ／ｋｇ群は０．６９９、ヒハツ末５００ｍｇ／ｋｇ群は０．２８９、ウコン末２０００ｍｇ／ｋｇとヒハツ末５００ｍｇ／ｋｇとの併用群は０．１０２である。Ｂｕｒｇｉ法（高木敬次郎他：薬物学、1987、南山堂参照）に則り算出した、ウコン末２０００ｍｇ／ｋｇ群とヒハツ末５００ｍｇ／ｋｇ群のそれぞれのＡＵＣ比の積は０．２０２であり、前記併用群の値よりも大きかった。すなわち、併用群における相乗効果が示された。
　以上より、従来からアルコール代謝を促進することが知られているウコンに比べて、ヒハツはより高いアルコール代謝能向上作用を有し、さらにヒハツとウコンとを併用することによりさらに高いアルコール代謝能向上効果が得られることが示された。 As shown in FIG. 1, when turmeric powder 2000 mg / kg was administered and when chickpea powder 500 mg / kg was administered, the blood ethanol concentration gradually increased with respect to the control, and the blood alcohol concentration was significant. The result was decreased. In addition, when administration of Hibatsu powder 500 mg / kg, blood ethanol concentration increases more slowly and blood alcohol concentration significantly decreases than when Turmeric powder 2000 mg / kg is administered. It became. In addition, when turmeric powder 2000 mg / kg and hihatsu powder 500 mg / kg are administered in combination, the increase in blood ethanol concentration is more gradual than in the case where only hihatsu powder 500 mg / kg is administered. The alcohol concentration was significantly reduced.
As shown in FIG. 2, even in the AUC having the average blood ethanol concentration in each group, when ethanol of 2000 mg / kg turmeric powder and 500 mg / kg of chickweed powder were administered, blood ethanol was significantly higher than the control. The concentration was significantly smaller. In addition, the administration of chickpea powder 500 mg / kg resulted in a significantly lower blood ethanol concentration than the administration of turmeric powder 2000 mg / kg. Furthermore, when turmeric powder 2000 mg / kg was administered in combination with hinah powder 500 mg / kg, the blood ethanol concentration was significantly smaller than when only 500 mg / kg of chickweed powder was administered. Here, the average AUC ratio of blood ethanol concentration in each group was 0.699 for the turmeric powder 2000 mg / kg group, 0.289 for the chickpea powder 500 mg / kg group, and 2000 mg / kg turmeric powder when the control was 1. And the combination group of Hihatsu powder 500 mg / kg is 0.102. The product of the AUC ratios of the turmeric powder 2000 mg / kg group and the hihatsu powder 500 mg / kg group calculated according to the Burgi method (Keijiro Takagi et al .: Pharmacology, 1987, see Nanzan-do) is 0.202, and the above combination Greater than the group value. That is, a synergistic effect in the combination group was shown.
From the above, compared with turmeric, which has been conventionally known to promote alcohol metabolism, hihatsu has a higher alcohol metabolic capacity improving effect, and further increases alcohol metabolic capacity by combining hihatsu and turmeric. It was shown that an effect can be obtained.
　以下の製造例１～１２に、本発明のアルコール濃度低下促進剤の製造例を示す。 The following production examples 1 to 12 show production examples of the alcohol concentration lowering accelerator of the present invention.
＜製造例１＞
　精製水（８０～９０℃）５００Ｌに安息香酸ナトリウム５００ｇ及びパラオキシ安息香酸エチル４０ｇ、精製白糖７０ｋｇ、カルメロースナトリウム３ｋｇを加え、攪拌しながら溶解させる。この液を冷却後、硝酸チアミン３７７ｇ及びリン酸水素ナトリウム１００ｇを加え、攪拌しながら溶解させる。別に精製水（８０～９０℃）２００Ｌに人参乾燥エキス１．４ｋｇ（人参として２０ｋｇ）及びヒハツ末（ジャワナガコショウ）０．５ｋｇ、ショウキョウエキス９７０ｇ（ショウキョウとして１０ｋｇ）、ウコン流エキス１１Ｌ(秋ウコンとして１１ｋｇ)、クエン酸１．５ｋｇ、酒石酸１．５ｋｇを加え、攪拌溶解した液を冷却後、ろ過する。これら２液を混合した後、ハッカ油１６７ｇ及びウイキョウ油３３ｇ、チョウジ油３３ｇを加え、攪拌しながら混合する。この混合液に精製水を適量加え、全量を１０００Ｌとすることにより、内服液を製した。 <Production Example 1>
To 500 L of purified water (80 to 90 ° C.), 500 g of sodium benzoate and 40 g of ethyl paraoxybenzoate, 70 kg of purified white sugar and 3 kg of carmellose sodium are added and dissolved while stirring. After cooling this solution, 377 g of thiamine nitrate and 100 g of sodium hydrogen phosphate are added and dissolved while stirring. Separately, 200 L of purified water (80-90 ° C), 1.4 kg of ginseng extract (20 kg as ginseng), 0.5 kg of Hihatu powder (Jawaga pepper), 970 g of pepper extract (10 kg as pepper), 11 L of turmeric extract ( 11 kg) of autumn turmeric, 1.5 kg of citric acid and 1.5 kg of tartaric acid are added, and the solution dissolved under stirring is cooled and filtered. After these two liquids are mixed, 167 g of mint oil, 33 g of fennel oil, and 33 g of clove oil are added and mixed while stirring. An appropriate amount of purified water was added to this mixed solution to make the total amount 1000 L, thereby preparing an internal solution.
＜製造例２＞
　精製水（８０～９０℃）５００Ｌに安息香酸ナトリウム５００ｇ及びパラオキシ安息香酸エチル４０ｇ、精製白糖７０ｋｇ、カルメロースナトリウム３ｋｇを加え、攪拌しながら溶解させる。この液を冷却後、硝酸チアミン３７７ｇ及びリン酸水素ナトリウム１００ｇを加え、攪拌しながら溶解させる。別に精製水（８０～９０℃）２００Ｌに人参乾燥エキス１．４ｋｇ（人参として２０ｋｇ）及びヒハツ末（インドナガコショウ）２ｋｇ、ショウキョウエキス９７０ｇ（ショウキョウとして１０ｋｇ）、ウコン流エキス１１Ｌ(秋ウコンとして１１ｋｇ)、クエン酸１．５ｋｇ、酒石酸１．５ｋｇを加え、攪拌溶解した液を冷却後、ろ過する。これら２液を混合した後、ハッカ油１６７ｇ及びウイキョウ油３３ｇ、チョウジ油３３ｇを加え、攪拌しながら混合する。この混合液に精製水を適量加え、全量を１０００Ｌとすることにより、内服液を製した。 <Production Example 2>
To 500 L of purified water (80 to 90 ° C.), 500 g of sodium benzoate and 40 g of ethyl paraoxybenzoate, 70 kg of purified white sugar and 3 kg of carmellose sodium are added and dissolved while stirring. After cooling this solution, 377 g of thiamine nitrate and 100 g of sodium hydrogen phosphate are added and dissolved while stirring. Separately, 200 kg of purified water (80-90 ° C.), 1.4 kg of dried carrot extract (20 kg as carrot), 2 kg of Hihatsu powder (Indian Naga pepper), 970 g of pepper extract (10 kg as pepper), 11 L of turmeric extract (autumn turmeric) 11 kg), 1.5 kg of citric acid and 1.5 kg of tartaric acid are added, and the solution dissolved under stirring is cooled and filtered. After these two liquids are mixed, 167 g of mint oil, 33 g of fennel oil, and 33 g of clove oil are added and mixed while stirring. An appropriate amount of purified water was added to this mixed solution to make the total amount 1000 L, thereby preparing an internal solution.
＜製造例３＞
　精製水（８０～９０℃）５００Ｌに安息香酸ナトリウム５００ｇ及びパラオキシ安息香酸エチル４０ｇ、精製白糖７０ｋｇ、カルメロースナトリウム３ｋｇを加え、攪拌しながら溶解させる。この液を冷却後、硝酸チアミン３７７ｇ及びリン酸水素ナトリウム１００ｇを加え、攪拌しながら溶解させる。別に精製水（８０～９０℃）２００Ｌに人参乾燥エキス１．４ｋｇ（人参として２０ｋｇ）及び黒胡椒１ｋｇ、ショウキョウエキス９７０ｇ（ショウキョウとして１０ｋｇ）、ウコン流エキス１１Ｌ(秋ウコンとして１１ｋｇ)、クエン酸１．５ｋｇ、酒石酸１．５ｋｇを加え、攪拌溶解した液を冷却後、ろ過する。これら２液を混合した後、ハッカ油１６７ｇ及びウイキョウ油３３ｇ、チョウジ油３３ｇを加え、攪拌しながら混合する。この混合液に精製水を適量加え、全量を１０００Ｌとすることにより、内服液を製した。 <Production Example 3>
To 500 L of purified water (80 to 90 ° C.), 500 g of sodium benzoate and 40 g of ethyl paraoxybenzoate, 70 kg of purified white sugar and 3 kg of carmellose sodium are added and dissolved while stirring. After cooling this solution, 377 g of thiamine nitrate and 100 g of sodium hydrogen phosphate are added and dissolved while stirring. Separately, 200L of purified water (80-90 ° C), 1.4kg of dried carrot extract (20kg as carrot), 1kg black pepper, 970g of pepper extract (10kg as pepper), 11L of turmeric extract (11kg as autumn turmeric), 1.5 kg of acid and 1.5 kg of tartaric acid are added, and the solution dissolved under stirring is cooled and then filtered. After these two liquids are mixed, 167 g of mint oil, 33 g of fennel oil, and 33 g of clove oil are added and mixed while stirring. An appropriate amount of purified water was added to this mixed solution to make the total amount 1000 L, thereby preparing an internal solution.
＜製造例４＞
　精製水（８０～９０℃）５００Ｌに安息香酸ナトリウム０．７ｋｇ及びパラオキシ安息香酸ブチル０．１４ｋｇ、精製白糖７０ｋｇ、カルメロースナトリウム６ｋｇを加え、攪拌しながら溶解させる。この液を冷却後、人参乾燥エキス１．８ｋｇ（人参として２５ｋｇ）及びヒハツ末（ジャワナガコショウ）３ｋｇ、ショウキョウ流エキス６Ｌ（ショウキョウとして６ｋｇ）、ウコン流エキス６Ｌ(秋ウコンとして６ｋｇ)、ウイキョウ流エキス６Ｌ（ウイキョウとして６ｋｇ）、チョウジ流エキス６Ｌ（チョウジとして６ｋｇ）、香料０．５Ｌを加え、攪拌溶解する。別に精製水（８０～９０℃）３００Ｌに合成ヒドロタルサイト６ｋｇを加え、攪拌混合した後、高圧ホモゲナイザーで循環分散する。分散液を冷却後、先の混合液と合わせたものに精製水を適量加え、全量を１０００Ｌとすることにより、内服液を調製した。 <Production Example 4>
To 500 L of purified water (80 to 90 ° C.), 0.7 kg of sodium benzoate and 0.14 kg of butyl paraoxybenzoate, 70 kg of purified white sugar and 6 kg of carmellose sodium are added and dissolved while stirring. After cooling this liquid, dried carrot extract 1.8 kg (25 kg as ginseng) and powdered lark (Java pepper) 3 kg, pepper extract 6 L (6 kg as pepper), turmeric extract 6 L (6 kg as autumn turmeric), Add 6 L of fennel extract (6 kg as fennel), 6 L of clove extract (6 kg as clove) and 0.5 L of fragrance, and dissolve with stirring. Separately, 6 kg of synthetic hydrotalcite is added to 300 L of purified water (80 to 90 ° C.), mixed with stirring, and then circulated and dispersed with a high-pressure homogenizer. After cooling the dispersion, an appropriate amount of purified water was added to the mixture with the previous mixture to make the total volume 1000 L, whereby an internal liquid was prepared.
＜製造例５＞
　精製水（８０～９０℃）５００Ｌに安息香酸ナトリウム０．７ｋｇ及びパラオキシ安息香酸ブチル０．１４ｋｇ、精製白糖７０ｋｇ、カルメロースナトリウム６ｋｇを加え、攪拌しながら溶解させる。この液を冷却後、人参乾燥エキス１．８ｋｇ（人参として２５ｋｇ）及びヒハツ末（インドナガコショウ）１ｋｇ、ショウキョウ流エキス６Ｌ（ショウキョウとして６ｋｇ）、ウコン流エキス６Ｌ(秋ウコンとして６ｋｇ)、ウイキョウ流エキス６Ｌ（ウイキョウとして６ｋｇ）、チョウジ流エキス６Ｌ（チョウジとして６ｋｇ）、香料０．５Ｌを加え、攪拌溶解する。別に精製水（８０～９０℃）３００Ｌに合成ヒドロタルサイト６ｋｇを加え、攪拌混合した後、高圧ホモゲナイザーで循環分散する。分散液を冷却後、先の混合液と合わせたものに精製水を適量加え、全量を１０００Ｌとすることにより、内服液を調製した。 <Production Example 5>
To 500 L of purified water (80 to 90 ° C.), 0.7 kg of sodium benzoate and 0.14 kg of butyl paraoxybenzoate, 70 kg of purified white sugar and 6 kg of carmellose sodium are added and dissolved while stirring. After cooling this liquid, dried carrot extract 1.8 kg (25 kg as carrot) and 1 kg hihitsu (Indaga pepper), 6 L pepper extract (6 kg as pepper), 6 L turmeric extract (6 kg as autumn turmeric), Add 6 L of fennel extract (6 kg as fennel), 6 L of clove extract (6 kg as clove) and 0.5 L of fragrance, and dissolve with stirring. Separately, 6 kg of synthetic hydrotalcite is added to 300 L of purified water (80 to 90 ° C.), mixed with stirring, and then circulated and dispersed with a high-pressure homogenizer. After cooling the dispersion, an appropriate amount of purified water was added to the mixture with the previous mixture to make the total volume 1000 L, whereby an internal liquid was prepared.
＜製造例６＞
　精製水（８０～９０℃）５００Ｌに安息香酸ナトリウム０．７ｋｇ及びパラオキシ安息香酸ブチル０．１４ｋｇ、精製白糖７０ｋｇ、カルメロースナトリウム６ｋｇを加え、攪拌しながら溶解させる。この液を冷却後、人参乾燥エキス１．８ｋｇ（人参として２５ｋｇ）及び黒胡椒０．５ｋｇ、ショウキョウ流エキス６Ｌ（ショウキョウとして６ｋｇ）、ウコン流エキス６Ｌ(秋ウコンとして６ｋｇ)、ウイキョウ流エキス６Ｌ（ウイキョウとして６ｋｇ）、チョウジ流エキス６Ｌ（チョウジとして６ｋｇ）、香料０．５Ｌを加え、攪拌溶解する。別に精製水（８０～９０℃）３００Ｌに合成ヒドロタルサイト６ｋｇを加え、攪拌混合した後、高圧ホモゲナイザーで循環分散する。分散液を冷却後、先の混合液と合わせたものに精製水を適量加え、全量を１０００Ｌとすることにより、内服液を調製した。 <Production Example 6>
To 500 L of purified water (80 to 90 ° C.), 0.7 kg of sodium benzoate and 0.14 kg of butyl paraoxybenzoate, 70 kg of purified white sugar and 6 kg of carmellose sodium are added and dissolved while stirring. After cooling this liquid, dried carrot extract 1.8kg (25kg as carrot), black pepper 0.5kg, pepper extract 6L (6kg as pepper), turmeric extract 6L (6kg as autumn turmeric), fennel extract Add 6L (6kg as fennel), 6L clove extract 6L (6kg as clove), 0.5L fragrance and stir and dissolve. Separately, 6 kg of synthetic hydrotalcite is added to 300 L of purified water (80 to 90 ° C.), mixed with stirring, and then circulated and dispersed with a high-pressure homogenizer. After cooling the dispersion, an appropriate amount of purified water was added to the mixture with the previous mixture to make the total volume 1000 L, whereby an internal liquid was prepared.
＜製造例７＞
　ヒハツ末（ジャワナガコショウ）４０質量部、ビタミンＢ１ ２５質量部、硬化油５０質量部、モノステアリン酸グリセリン２０質量部、トウモロコシデンプン１５質量部、カルメロースカルシウム１５質量部からなる混合末にエタノール１２質量部を加え練合物を製した。練合物を押出し造粒し（φ０．８mm）、乾燥、整粒、分級し顆粒を得た（以下Ａ顆粒と称する）。
　また、乾燥水酸化アルミニウムゲル４５０質量部、水酸化マグネシウム３２５質量部、合成ヒドロタルサイト４５０質量部、カンゾウエキス末７５質量部、ウイキョウ末２００質量部、ウコン末（秋ウコン）２００質量部、ニンジン乾燥エキス２０質量部、ポリビニルアルコール７０質量部、カルメロースカルシウム３０質量部、結晶セルロース４０質量部、キシリトール１５４５質量部からなる混合末に７０％エタノール８００質量部を加え練合物を製した。練合物を押出し造粒し（φ０．８mm）、乾燥、整粒、分級し、顆粒を得た（以下Ｂ顆粒と称する）。
　さらにメタケイ酸アルミン酸マグネシウム２４質量部にｌ－メントール６質量部を吸着させ、香料末を得た（以下Ｃ香料末と称する）。
　Ａ顆粒１６５質量部、Ｂ顆粒３４０５質量部、Ｃ香料末３０質量部を混合機にて混合し、さらに分包機にて分包し１回服用量１．２gの顆粒剤を得た。 <Production Example 7>
Ethanol 12 in a mixed powder consisting of 40 parts by weight of Hihatsu powder, 25 parts by weight of vitamin B1, 50 parts by weight of hardened oil, 20 parts by weight of glyceryl monostearate, 15 parts by weight of corn starch and 15 parts by weight of carmellose calcium A mass part was added and the kneaded material was manufactured. The kneaded product was extruded and granulated (φ0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as A granules).
Also, 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), carrot A kneaded product was prepared by adding 800 parts by mass of 70% ethanol to a mixed powder comprising 20 parts by mass of a dry extract, 70 parts by mass of polyvinyl alcohol, 30 parts by mass of carmellose calcium, 40 parts by mass of crystalline cellulose, and 1545 parts by mass of xylitol. The kneaded product was extruded and granulated (φ0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as B granules).
Further, 6 parts by mass of l-menthol was adsorbed on 24 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder).
165 parts by mass of A granule, 3405 parts by mass of B granule, and 30 parts by mass of C fragrance powder were mixed by a mixer, and further packed by a packaging machine to obtain a granule having a single dose of 1.2 g.
＜製造例８＞
　ヒハツ末（インドナガコショウ）４０質量部、ビタミンＢ１ ２５質量部、硬化油５０質量部、モノステアリン酸グリセリン２０質量部、トウモロコシデンプン１５質量部、カルメロースカルシウム１５質量部からなる混合末にエタノール１２質量部を加え練合物を製した。練合物を押出し造粒し（φ０．８mm）、乾燥、整粒、分級し顆粒を得た（以下Ａ顆粒と称する）。
　また、乾燥水酸化アルミニウムゲル４５０質量部、水酸化マグネシウム３２５質量部、合成ヒドロタルサイト４５０質量部、カンゾウエキス末７５質量部、ウイキョウ末２００質量部、ウコン末（秋ウコン）２００質量部、ニンジン乾燥エキス２０質量部、ポリビニルアルコール７０質量部、カルメロースカルシウム３０質量部、結晶セルロース４０質量部、キシリトール１５４５質量部からなる混合末に７０％エタノール８００質量部を加え練合物を製した。練合物を押出し造粒し（φ０．８mm）、乾燥、整粒、分級し、顆粒を得た（以下Ｂ顆粒と称する）。
　さらにメタケイ酸アルミン酸マグネシウム２４質量部にｌ－メントール６質量部を吸着させ、香料末を得た（以下Ｃ香料末と称する）。
　Ａ顆粒１６５質量部、Ｂ顆粒３４０５質量部、Ｃ香料末３０質量部を混合機にて混合し、さらに分包機にて分包し１回服用量１．２gの顆粒剤を得た。 <Production Example 8>
Ethanol 12 A mass part was added and the kneaded material was manufactured. The kneaded product was extruded and granulated (φ0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as A granules).
Also, 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), carrot A kneaded product was prepared by adding 800 parts by mass of 70% ethanol to a mixed powder comprising 20 parts by mass of a dry extract, 70 parts by mass of polyvinyl alcohol, 30 parts by mass of carmellose calcium, 40 parts by mass of crystalline cellulose, and 1545 parts by mass of xylitol. The kneaded product was extruded and granulated (φ0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as B granules).
Further, 6 parts by mass of l-menthol was adsorbed on 24 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder).
165 parts by mass of A granule, 3405 parts by mass of B granule, and 30 parts by mass of C fragrance powder were mixed by a mixer, and further packed by a packaging machine to obtain a granule having a single dose of 1.2 g.
＜製造例９＞
　黒胡椒４０質量部、ビタミンＢ１ ２５質量部、硬化油５０質量部、モノステアリン酸グリセリン２０質量部、トウモロコシデンプン１５質量部、カルメロースカルシウム１５質量部からなる混合末にエタノール１２質量部を加え練合物を製した。練合物を押出し造粒し（φ０．８mm）、乾燥、整粒、分級し顆粒を得た（以下Ａ顆粒と称する）。
　また、乾燥水酸化アルミニウムゲル４５０質量部、水酸化マグネシウム３２５質量部、合成ヒドロタルサイト４５０質量部、カンゾウエキス末７５質量部、ウイキョウ末２００質量部、ウコン末（秋ウコン）２００質量部、ニンジン乾燥エキス２０質量部、ポリビニルアルコール７０質量部、カルメロースカルシウム３０質量部、結晶セルロース４０質量部、キシリトール１５４５質量部からなる混合末に７０％エタノール８００質量部を加え練合物を製した。練合物を押出し造粒し（φ０．８mm）、乾燥、整粒、分級し、顆粒を得た（以下Ｂ顆粒と称する）。
　さらにメタケイ酸アルミン酸マグネシウム２４質量部にｌ－メントール６質量部を吸着させ、香料末を得た（以下Ｃ香料末と称する）。
　Ａ顆粒１６５質量部、Ｂ顆粒３４０５質量部、Ｃ香料末３０質量部を混合機にて混合し、さらに分包機にて分包し１回服用量１．２gの顆粒剤を得た。 <Production Example 9>
Add 12 parts by mass of ethanol to the mixed powder consisting of 40 parts by mass of black pepper, 25 parts by mass of vitamin B1, 50 parts by mass of hardened oil, 20 parts by mass of glyceryl monostearate, 15 parts by mass of corn starch and 15 parts by mass of carmellose calcium. A compound was made. The kneaded product was extruded and granulated (φ0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as A granules).
Also, 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), carrot A kneaded product was prepared by adding 800 parts by mass of 70% ethanol to a mixed powder comprising 20 parts by mass of a dry extract, 70 parts by mass of polyvinyl alcohol, 30 parts by mass of carmellose calcium, 40 parts by mass of crystalline cellulose, and 1545 parts by mass of xylitol. The kneaded product was extruded and granulated (φ0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as B granules).
Further, 6 parts by mass of l-menthol was adsorbed on 24 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder).
165 parts by mass of A granule, 3405 parts by mass of B granule, and 30 parts by mass of C fragrance powder were mixed by a mixer, and further packed by a packaging machine to obtain a granule having a single dose of 1.2 g.
＜製造例１０＞
　ヒハツ末（ジャワナガコショウ）３０質量部、ビタミンＢ１ ２５質量部、硬化油５５質量部、モノステアリン酸グリセリン２５質量部、トウモロコシデンプン１５質量部、カルメロースカルシウム１５質量部からなる混合末にエタノール１２質量部を加え練合物を製した。練合物を押出し造粒し（φ０．５ｍｍ）、乾燥、整粒し顆粒を得た（以下Ａ顆粒と称する）。
　また、乾燥水酸化アルミニウムゲル４５０質量部、水酸化マグネシウム３２５質量部、合成ヒドロタルサイト４５０質量部、カンゾウエキス末７５質量部、ウイキョウ末２００質量部、ウコン末（秋ウコン）２００質量部、ショウキョウ末１００質量部、ニンジン乾燥エキス２０質量部、ヒドロキシプロピルセルロース９０質量部、カルメロースカルシウム３０質量部、結晶セルロース３０質量部、エリスリトール１４４５質量部からなる混合末に９０％エタノール７００質量部を加え練合物を製した。練合物を乾燥、整粒し顆粒を得た（以下Ｂ顆粒と称する）。
　さらにメタケイ酸アルミン酸マグネシウム１６質量部にｌ－メントール４質量部を吸着させ、香料末を得た（以下Ｃ香料末と称する）。
　Ａ顆粒１６５質量部、Ｂ顆粒３４１５質量部、Ｃ香料末２０質量部を混合機にて混合し、さらに分包機にて分包し１回服用量１．２gの顆粒剤を得た。 <Production Example 10>
Ethanol 12 in a mixed powder consisting of 30 parts by weight of Hihatsu powder, 25 parts by weight of vitamin B1, 55 parts by weight of hardened oil, 25 parts by weight of glyceryl monostearate, 15 parts by weight of corn starch and 15 parts by weight of carmellose calcium A mass part was added and the kneaded material was manufactured. The kneaded product was extruded and granulated (φ0.5 mm), dried and sized to obtain granules (hereinafter referred to as A granules).
Also, 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), show Add 700 parts by mass of 90% ethanol to a mixed powder consisting of 100 parts by mass of carp powder, 20 parts by mass of dried carrot extract, 90 parts by mass of hydroxypropyl cellulose, 30 parts by mass of carmellose calcium, 30 parts by mass of crystalline cellulose, and 1445 parts by mass of erythritol. A kneaded product was made. The kneaded product was dried and sized to obtain granules (hereinafter referred to as B granules).
Further, 4 parts by mass of l-menthol was adsorbed on 16 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder).
165 parts by mass of A granules, 3415 parts by mass of B granules, and 20 parts by mass of C fragrance powder were mixed with a mixer and further packaged with a packaging machine to obtain a granule having a single dose of 1.2 g.
＜製造例１１＞
　ヒハツ末（インドナガコショウ）３０質量部、ビタミンＢ１ ２５質量部、硬化油５５質量部、モノステアリン酸グリセリン２５質量部、トウモロコシデンプン１５質量部、カルメロースカルシウム１５質量部からなる混合末にエタノール１２質量部を加え練合物を製した。練合物を押出し造粒し（φ０．５ｍｍ）、乾燥、整粒し顆粒を得た（以下Ａ顆粒と称する）。
　また、乾燥水酸化アルミニウムゲル４５０質量部、水酸化マグネシウム３２５質量部、合成ヒドロタルサイト４５０質量部、カンゾウエキス末７５質量部、ウイキョウ末２００質量部、ウコン末（秋ウコン）２００質量部、ショウキョウ末１００質量部、ニンジン乾燥エキス２０質量部、ヒドロキシプロピルセルロース９０質量部、カルメロースカルシウム３０質量部、結晶セルロース３０質量部、エリスリトール１４４５質量部からなる混合末に９０％エタノール７００質量部を加え練合物を製した。練合物を乾燥、整粒し顆粒を得た（以下Ｂ顆粒と称する）。
　さらにメタケイ酸アルミン酸マグネシウム１６質量部にｌ－メントール４質量部を吸着させ、香料末を得た（以下Ｃ香料末と称する）。
　Ａ顆粒１６５質量部、Ｂ顆粒３４１５質量部、Ｃ香料末２０質量部を混合機にて混合し、さらに分包機にて分包し１回服用量１．２gの顆粒剤を得た。 <Production Example 11>
Ethanol 12 A mass part was added and the kneaded material was manufactured. The kneaded product was extruded and granulated (φ0.5 mm), dried and sized to obtain granules (hereinafter referred to as A granules).
Also, 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), show Add 700 parts by mass of 90% ethanol to a mixed powder consisting of 100 parts by mass of carp powder, 20 parts by mass of dried carrot extract, 90 parts by mass of hydroxypropyl cellulose, 30 parts by mass of carmellose calcium, 30 parts by mass of crystalline cellulose, and 1445 parts by mass of erythritol. A kneaded product was made. The kneaded product was dried and sized to obtain granules (hereinafter referred to as B granules).
Further, 4 parts by mass of l-menthol was adsorbed on 16 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder).
165 parts by mass of A granules, 3415 parts by mass of B granules, and 20 parts by mass of C fragrance powder were mixed with a mixer and further packaged with a packaging machine to obtain a granule having a single dose of 1.2 g.
＜製造例１２＞
　黒胡椒３０質量部、ビタミンＢ１ ２５質量部、硬化油５５質量部、モノステアリン酸グリセリン２５質量部、トウモロコシデンプン１５質量部、カルメロースカルシウム１５質量部からなる混合末にエタノール１２質量部を加え練合物を製した。練合物を押出し造粒し（φ０．５ｍｍ）、乾燥、整粒し顆粒を得た（以下Ａ顆粒と称する）。
　また、乾燥水酸化アルミニウムゲル４５０質量部、水酸化マグネシウム３２５質量部、合成ヒドロタルサイト４５０質量部、カンゾウエキス末７５質量部、ウイキョウ末２００質量部、ウコン末（秋ウコン）２００質量部、ショウキョウ末１００質量部、ニンジン乾燥エキス２０質量部、ヒドロキシプロピルセルロース９０質量部、カルメロースカルシウム３０質量部、結晶セルロース３０質量部、エリスリトール１４４５質量部からなる混合末に９０％エタノール７００質量部を加え練合物を製した。練合物を乾燥、整粒し顆粒を得た（以下Ｂ顆粒と称する）。
　さらにメタケイ酸アルミン酸マグネシウム１６質量部にｌ－メントール４質量部を吸着させ、香料末を得た（以下Ｃ香料末と称する）。
　Ａ顆粒１６５質量部、Ｂ顆粒３４１５質量部、Ｃ香料末２０質量部を混合機にて混合し、さらに分包機にて分包し１回服用量１．２gの顆粒剤を得た。 <Production Example 12>
30 parts by weight of black pepper, 25 parts by weight of vitamin B1, 55 parts by weight of hardened oil, 25 parts by weight of glyceryl monostearate, 15 parts by weight of corn starch and 15 parts by weight of carmellose calcium are added with 12 parts by weight of ethanol and kneaded. A compound was made. The kneaded product was extruded and granulated (φ0.5 mm), dried and sized to obtain granules (hereinafter referred to as A granules).
Also, 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), show Add 700 parts by mass of 90% ethanol to a mixed powder consisting of 100 parts by mass of carp powder, 20 parts by mass of dried carrot extract, 90 parts by mass of hydroxypropyl cellulose, 30 parts by mass of carmellose calcium, 30 parts by mass of crystalline cellulose, and 1445 parts by mass of erythritol. A kneaded product was made. The kneaded product was dried and sized to obtain granules (hereinafter referred to as B granules).
Further, 4 parts by mass of l-menthol was adsorbed on 16 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder).
165 parts by mass of A granules, 3415 parts by mass of B granules, and 20 parts by mass of C fragrance powder were mixed with a mixer and further packaged with a packaging machine to obtain a granule having a single dose of 1.2 g.
　本発明の薬剤は、ピペリン又はピペリン含有生薬と、ウコンとを含有するため、アルコール摂取後のもたれ、吐き気、二日酔い等の不快な諸症状を速やかに改善することができる。 Since the drug of the present invention contains piperine or a piperine-containing crude drug and turmeric, unpleasant symptoms such as leaning, nausea and hangover after alcohol consumption can be quickly improved.

Claims (5)

  1. 　ピペリン又はピペリン含有生薬を含有する血中アルコール濃度低下促進剤。 Accelerator for lowering blood alcohol concentration containing piperine or piperine-containing crude drugs.
  2. 　前記ピペリン含有生薬を含有する請求項１に記載の血中アルコール濃度低下促進剤。 The blood alcohol concentration lowering accelerator according to claim 1, comprising the piperine-containing crude drug.
  3. 　前記ピペリン含有生薬がヒハツである請求項１又は２に記載の血中アルコール濃度低下促進剤。 3. The blood alcohol concentration lowering accelerator according to claim 1 or 2, wherein the piperine-containing crude drug is Hihatsu.
  4. 　さらにウコンを含有する請求項１～３のいずれか１項記載の血中アルコール濃度低下促進剤。 The blood alcohol concentration lowering promoter according to any one of claims 1 to 3, further comprising turmeric.
  5. 　請求項１～４のいずれか１項に記載の血中アルコール濃度低下促進剤を含有する医薬品又は飲食品。 A pharmaceutical or a food or drink containing the blood alcohol concentration lowering promoter according to any one of claims 1 to 4.
PCT/JP2013/068930 2012-07-11 2013-07-11 Superior blood alcohol concentration reduction accelerating agent WO2014010656A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014524858A JPWO2014010656A1 (en) 2012-07-11 2013-07-11 Excellent promoter for lowering blood alcohol levels

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012-155745 2012-07-11
JP2012155745 2012-07-11
JP2012-155738 2012-07-11
JP2012155738 2012-07-11

Publications (1)

Publication Number Publication Date
WO2014010656A1 true WO2014010656A1 (en) 2014-01-16

Family

ID=49916097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/068930 WO2014010656A1 (en) 2012-07-11 2013-07-11 Superior blood alcohol concentration reduction accelerating agent

Country Status (2)

Country Link
JP (1) JPWO2014010656A1 (en)
WO (1) WO2014010656A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015077124A (en) * 2013-09-13 2015-04-23 大正製薬株式会社 Beverage
JP5801515B1 (en) * 2014-05-08 2015-10-28 アサヒグループホールディングス株式会社 Tomato-containing food and drink
WO2016084290A1 (en) * 2014-11-25 2016-06-02 アサヒグループホールディングス株式会社 Food or beverage containing fruit-derived component
JP2017025056A (en) * 2015-07-27 2017-02-02 大正製薬株式会社 Piperine-containing oral composition
US20230248710A1 (en) * 2022-02-05 2023-08-10 Ajay Perecherla Synergistic composition for veisalgia prevention
JP7489136B2 (en) 2020-01-27 2024-05-23 株式会社東洋新薬 Liver function improver

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05262646A (en) * 1992-03-23 1993-10-12 Takeda Chem Ind Ltd Hepatic disorder-inhibiting agent
JPH0899890A (en) * 1994-10-04 1996-04-16 Kowa Co Gastrointestinal solution for internal use
WO2005032569A1 (en) * 2003-10-02 2005-04-14 Kowa Co., Ltd. Medicinal composition
JP2005112846A (en) * 2003-09-17 2005-04-28 Lequio Pharma Co Ltd Turmeric-containing composition
JP2006104109A (en) * 2004-10-04 2006-04-20 Maruzen Pharmaceut Co Ltd Ameliorating agent for dropsical feeling and food and drink for ameliorating dropsical feeling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100968674B1 (en) * 2008-02-04 2010-07-06 강홍구 Herbal composition for alcoholic hangover
KR101046787B1 (en) * 2009-02-18 2011-07-05 황동철 Hangover drink composition
KR101176590B1 (en) * 2010-05-26 2012-08-23 이성훈 Herbal Composition for Removing Hangover and Beverage Containing the Same
JP2012031080A (en) * 2010-07-29 2012-02-16 House Foods Corp Recovery agent for symptom of hangover

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05262646A (en) * 1992-03-23 1993-10-12 Takeda Chem Ind Ltd Hepatic disorder-inhibiting agent
JPH0899890A (en) * 1994-10-04 1996-04-16 Kowa Co Gastrointestinal solution for internal use
JP2005112846A (en) * 2003-09-17 2005-04-28 Lequio Pharma Co Ltd Turmeric-containing composition
WO2005032569A1 (en) * 2003-10-02 2005-04-14 Kowa Co., Ltd. Medicinal composition
JP2006104109A (en) * 2004-10-04 2006-04-20 Maruzen Pharmaceut Co Ltd Ameliorating agent for dropsical feeling and food and drink for ameliorating dropsical feeling

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015077124A (en) * 2013-09-13 2015-04-23 大正製薬株式会社 Beverage
JP2020150953A (en) * 2013-09-13 2020-09-24 大正製薬株式会社 Beverage
JP5801515B1 (en) * 2014-05-08 2015-10-28 アサヒグループホールディングス株式会社 Tomato-containing food and drink
WO2015170605A1 (en) * 2014-05-08 2015-11-12 アサヒグループホールディングス株式会社 Tomato-containing food or drink
WO2016084290A1 (en) * 2014-11-25 2016-06-02 アサヒグループホールディングス株式会社 Food or beverage containing fruit-derived component
JPWO2016084290A1 (en) * 2014-11-25 2017-09-07 アサヒグループホールディングス株式会社 Food and beverage containing fruits
JP2017025056A (en) * 2015-07-27 2017-02-02 大正製薬株式会社 Piperine-containing oral composition
JP7489136B2 (en) 2020-01-27 2024-05-23 株式会社東洋新薬 Liver function improver
US20230248710A1 (en) * 2022-02-05 2023-08-10 Ajay Perecherla Synergistic composition for veisalgia prevention

Also Published As

Publication number Publication date
JPWO2014010656A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
WO2014010656A1 (en) Superior blood alcohol concentration reduction accelerating agent
CN104922145B (en) Composition of γ-aminobutyric acid and chitosan oligosaccharide and its preparation method and application
US10111451B2 (en) Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor
EP2070545A1 (en) Oral compositions for the prevention and treatment of inflammatory disorders of the colon
EP2303297B1 (en) Water-soluble extracts of artemisia dracunculus (tarragon) for improvement of glucose metabolism
JP2014510736A (en) Drug composition for suppressing blood sugar, lipemia and body weight
JPWO2007043363A1 (en) Composition for suppressing hypoglycemia symptoms
WO2014010658A1 (en) Preparation containing indian long pepper
CN104840800B (en) Bamboo-leaves flavones and the composition of γ-aminobutyric acid and its preparation method and application
JP2014114253A (en) Analgesic antiinflammatory composition containing crude drug
KR101910013B1 (en) A composition for improving, preventing and treating of pain comprising herb extract
JP4667244B2 (en) Pharmaceutical composition
JP4355967B2 (en) Pharmaceutical composition
KR101528557B1 (en) A pharmaceutical composition comprising fermented Eastern prickly pear
WO2017084631A1 (en) Composition for preventing or treating pancreas fatty infiltration and relieving pancreatic lesions, diabetes or other related symptoms caused by pancreas fatty infiltration, and method
KR20200140103A (en) Composition for preventing or treating tic disorder, tourette&#39;s disorder or obsessive-compulsive disorder
JP5823131B2 (en) A composition containing windproof tsushosan
JP6771274B2 (en) Oral composition
JP6114133B2 (en) Kokushi extract-containing oral solution, solubilizer and solubilization method
KR102482128B1 (en) Compositions containing new methylsulfonylmethane(MSM) with increased arthritis treatment effect and the process of manufacture thereof
JP2002371001A (en) Prophylactic or therapeutic agent for cataract
JP7503424B2 (en) Coenzyme Q10 stabilizing composition, composition for stabilizing coenzyme Q10, and method for stabilizing coenzyme Q10
JP5452042B2 (en) Pharmaceutical composition
JP2002212085A (en) Uric acid value-reducing agent
KR101570154B1 (en) A method for preparing fermented Eastern prickly pear

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13816701

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014524858

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014/16392

Country of ref document: TR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13816701

Country of ref document: EP

Kind code of ref document: A1